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Abstract 
Abstract 
New drug treatments have revolutionised the care of people with HIV, but they 
require exceptionally high levels of adherence. Research into the risk factors has been 
predominantly empirically rather than theoretically driven. Studies of adherence in 
other conditions have established the importance of perceived self-efficacy. Research 
studies exploring this relationship in HIV were conducted when the only available 
treatment wz.s monotherapy, or with an exclusively female sample. 
This study attempted to investigate the role of self-efficacy to adherence to 
antiretroviral medications in a UK sample of HIV positive people. It also aimed to 
explore the relationship between self-efficacy and depression. Finally, the 
relationship between self-efficacy and coping strategies was also considered. The 
study employed a cross-sectional design, with all participants completing a 
questionnaire at one time point. 
Multiple regression analysis of the predictors of dose delays established that 
the two medication-specific self-efficacy measures accounted for 42.9% of the 
variance. No other predictors emerged from a stepwise regression. 
Use of recreational drugs was the only predictor of dose omissions to emerge 
from a multiple regression. However, when drug use was controlled for, self-efficacy 
for adherence added a further 12.7% of the variance. 
The findings of this study suggest that self-efficacy is related to adherence 
although the direction of causality remains to be established. Clearly, further research 
is needed to clarify the role of self-efficacy. Should it prove to be as significant as the 
results of this study imply, it is quickly and easily assessed and, moreover amenable 
to intervention. 
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1. Introduction 
1.1 General Introduction 
"Keep a watch also on the faults of the patients, which often make them lie about the 
taking of things prescribed. For through not taking disagreeable drinks, purgative or 
other, they sometimes die . .. (Hippocrates, On Decorum, cited in DiMatteo & DiNicola, 
1982, p.9) 
Concern about adherence to medical recommendations has a long, if not necessarily 
honourable history. Fortunately, there have been significant advances in the 
understanding of adherence, even if the gains are not commensurate with those in the 
medical treatments prescribed. 
1.2 HIV and the Importance of Adherence 
Scientific breakthroughs mean that even for conditions once thought fatal and incurable, 
effective treatments are available. Most recently, the development of Highly Active 
Antiretroviral Therapy (HAAR T), also called combination drug therapy, has 
revolutionised the care of people with HIV (Human Immunodeficiency Virus). 
HIV 
HIV suppresses the immune system leaving it vulnerable to opportunistic infections. 
The condition was first identified in the United States in 1981, but the virus itself was 
not isolated until 1983, allowing for the development of tests detecting the presence of 
antibodies to the virus. People testing positive for antibodies to HIV are termed "HIV 
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positive", and those testing negative "HIV negative". The virus invades particular cells 
in the immune system, CD4 cells. The number of CD4 cells per cubic mm of blood 
provides a rough estimate of the strength of the immune system. A count of less than 
200 per cubic mm indicates that the body is vulnerable to opportunistic infections. 
These may affect the lungs, such as (pneumocystis carinii pneumonia, PCP), the 
digestive system, (cryptosporidiosis), the brain and the central nervous system, 
(toxoplasmosis) and the eyes, (cytomegalovirus). HIV is also associated with particular 
types of tumour, such as Kaposi's sarcoma and lymphoma. HIV itself can enter the 
brain and cause a form of subcortical dementia. The presence of one of these 
conditions, (or a number of others) indicates a compromised immune system and is 
sufficient for a diagnosis of AIDS (Acquired Immune Deficiency Syndrome) to be 
made, although this term has fallen into disuse. 
Means of Transmission 
HIV is transmitted through body fluids, usually via sexual intercourse, by infected blood 
products, by the use of infected syringes during the injection of drugs, or by foetal 
transmission in utero. 
Incidence 
Worldwide, the spread of HI V has reached epidemic proportions, with HIV the leading 
cause of death in many African countries and several US cities, (Schoub, 1994). In the 
UK, over 24,000 people are known to be infected with the virus. 
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Treatment 
Treatment trials have demonstrated that, in combination, the new drugs can prevent the 
virus from replicating over the long term, such that the amount of HIV contained in 
plasma is beneath detectable levels. Unfortunately, this does not mean the virus has 
been eradicated since it can survive in other parts of the body. The new combination 
drug therapies are considered largely responsible for a 48% decline in deaths from 
AIDS, and a 12% decrease in incidence last year, (De cock, 1998, cited in Hedge & 
Petrak, 1998). This has been referred to as the Lazarus effect, offering even those 
thought to be dying, a "second life" (Rabkin & Ferrando, 1997). Nonetheless, the new 
treatments have not provided miracle cures for everyone, and chief among the culprits 
are the development of drug resistance, and non-adherence to the drug regimens. 
Adherence to these requires considerable self-discipline. Patients are required to take up 
to thirty pills a day, at precise time intervals and often under strict nutritional conditions. 
For example, some pills must be refrigerated, some taken with food, some without, and 
some a couple of hours after eating. Incorporating such a regime into daily life is no 
mean feat, regardless of the degree of motivation. Some of these drugs also have side-
effects including anaemia, nausea, diarrhoea, lipodystrophy, leukopenia, neutropenia 
and peripheral neuropathy. 
The effects of non-adherence 
The potential consequences of non-adherence are grave, both for the individual and for 
public health. When doses are missed, plasma drug concentrations fall below the level 
required to suppress viral replication. During these periods, the virus replicates up to 
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ten billion times a day, and mutates approximately once every ten thousand replications, 
(Chesney 1998, cited in Levine, 1998). Some of these mutations will have the potential 
to replicate in the presence of the antiretroviral drugs. The drugs may inhibit the non-
mutated strain and leave a fertile environment for the drug resistant strain to flourish. 
Resistance to antiretroviral medication develops rapidly, within days of missed or 
subtherapeutic dosing, (Cinat! et al. 1994, Moutouh et al. 1996, cited in Mehta, Moore, 
& Graham, 1997, Ho, 1996, cited in Rabkin & Ferrando, 1997). Resistance to one class 
of drugs, protease inhibitors, can develop in a week, (Rabkin & Ferrando, 1997). 
Furthermore, resistance to one drug often entails resistance to other drugs in the same 
class, referred to as cross-resistance. This, therefore, may limit future treatment options 
dramatically. 
The picture for those with HIV, then, is markedly different from those with other 
chronic conditions such as hypertension. The latter, if initially nonadherent, can 
recommence treatment at a later date without adverse consequences. That option is not 
available for those with HIV whose initial non-adherence has led to drug resistance. 
Subsequent treatment with the drug may also fail. This means that these patients may 
have only one opportunity with each drug. Adherence appears to be most crucial at the 
start of treatment, (Hall & Conway, 1997, cited in Birch, 1998, Lange, Reijers, & 
Weverling, 1998). Thus, it is most important when patients are unfamiliar with their 
medications, have not learned to integrate them into their routines, and are most likely 
to experience side-effects. 
There appears to be a very direct relationship between adherence and the amount 
of virus in the body. One study, (Patterson, Swindells, Mohr, Brester, Vergis, Squier, 
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Wagener & Singh, 1999) used an electronic measuring device to plot the relationship 
between adherence at the start of treatment and the achievement of an undetectable viral 
load. They found that 81 % of those maintaining adherence levels of over 95% had 
undetectable viral loads three months later. A 5% drop in adherence to 90-95% had a 
dramatic effect in terms of the proportion achieving this goal, 64%. By comparison, 
50% of those managing 80-90% adherence had undetectable viral loads, and only 25% 
of those with 70-80% adherence. These rates plummet to just 6% for those whose 
adherence rates fall beneath the 70% threshold. 
Other clinical markers, CD4 cell counts show a similar pattern, increasing by an 
average of 60 cells per cubic mm when adherence levels are greater than 95%. When 
adherence drops beneath 80%, CD4 counts decrease by 13 cells per cubic mm, 
(Chaisson, 1999). 
95% adherence roughly translates as missing (or delaying) one dose a week. 
Should this happen twice a week, adherence drops to 90%. 
In addition to the deleterious consequences for the patient, should viral 
transmission occur, the newly infected person(s) may carry the drug resistant strain. 
This raises the possibility of the development of multi drug resistant strains of HIV, (as 
happened with tuberculosis, Bloom et a1. 1992, Sumartojo, 1993, cited in Ickovics & 
Meisler, 1997, Edlin et a1. 1992, cited in Mehta et a1.1997), which constitutes a major 
threat to public health. 
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1.3 Methodological Issues in "IV Adherence Research 
Given this alarming situation, it is, perhaps, unsurprising that adherence has shot up the 
agenda of those working with HIV. Some of the pressure may be driven by the quest 
for sociodemographic, behavioural or personality variables predictive of non-adherence, 
so as to exclude these groups (such as injecting drug users) or individuals from 
treatment, (Eldred, Wu, Chaisson & Moore, 1997). 
Unfortunately, the measurement of adherence is riven with methodological 
problems. The language itself remains contentious. Some authors use the term 
compliance but "adherence" is generally preferred because it avoids connotations of 
passive obedience. Labelling people "non compliant" sounds judgmental and implies 
any departure from medical recommendations is the patient's responsibility. "Non-
compliance is the failure of the patient to fulfil the clinical prescription as it was 
intended by the practitioner" (Hays & DiMatteo, 1987, p. 38). Adherence, similarly, 
has been variously defined, but the classic and widely quoted definition is Haynes' "the 
extent to which a person's behaviour (in terms of taking medications, follOWing diets, or 
executing lifestyle changes) coincides with medical or health advice" (Haynes, 1979, 
cited in Epstein & C1uss, 1982, p.2-3). Adherence is a continuous not a dichotomous 
variable and most non-adherence is partial not total, so it seems more constructive to 
define the extent of adherence as precisely as possible, especially since particular levels 
of adherence are associated with differing clinical outcomes in HIV, (Patterson et 
al.I999). 
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Within Health Psychology, adherence has been conventionally defined as taking more 
than 80% of one's medication. However, the adoption of such a definition within HIV 
is untenable for a number of reasons. Evaluation of adherence must also consider the 
threshold of therapy necessary for effectiveness, (Mehta et al. 1997). As yet, the 
specific quantities of each antiretroviral drug required to achieve viral suppression 
remains undetermined. However, recent research suggests, (Gulick, Mellors, Havlir et 
al. 1996, and Myers & Montaner, 1996, both cited in Mehta et al. 1997) that 90-100% of 
doses must be taken to suppress viral replication. Moreover, in the context of HI V, 
adherence entails more than the consumption of the requisite number of pills. The 
timing of doses, and the following of special dietary requirements, or the refrigeration of 
medications becomes equally important. Few drug assays exist for antirtroviral 
medications and they are not regarded as fail safe measures of adherence because of 
individual differences in the way the drugs are absorbed, metabolised, and excreted 
from the body, (Rainsford, 1999). Measuring adherence under these conditions presents 
methodological challenges, and many studies continue to use a predetermined standard 
of self-reported adherence and classify adherence as the percentage of people achieving 
this goal, (Broers, Morabia, Hirschel, 1994, Samet, Libman, Steger et aI., 1992, Samuels, 
Hendrix, Hilton, Marantz, Sloan, & Small, 1990, cited in Eldred et al. 1997, Nakashima, 
Jones, Burgess, & Ward, 1998, Singh, Squier, Sivek, Wagener, Hong Nguyen, & Yu, 
1996). Some researchers have chosen to rely on pill counts (Durvasula, Galin, & 
Stefaniak, 1998). Patients are required to bring their pill bottles to appointments and the 
number of pills remaining is subtracted from the total calculated. Unfortunately, this 
method takes no account of whether the pills were taken at the correct times. 
7 
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Nonadherent patients, aware that their pills will be counted, may dispose of them before 
their appointment, a phenomenon known as pill dumping, (lckowics & Meisler, 1997). 
Data collected using this method probably represents an overestimate of adherence 
(Rudd, Byyny, Zachary et al. 1989, and Cramer, Mattson, Prevey et al., 1989, cited in 
Ickowics & Meisler, 1997). In an effort to address this problem, some researchers, 
(Bangsberg et al. 1998, cited in Levine, 1998) have resorted to random unannounced pill 
counts. Technological advances have led to the design of pill bottles incorporating 
computer chips in their lids which record each date and time that the bottle is opened. 
However, as Epstein & Cluss (1982) point out, "these methods do not actually measure 
medication use but rather measure use of the medication dispenser. " Epstein & Cluss, 
1982, p. 953). The Medication Event Monitoring System (MEMS) potentially provides 
more accurate information about whether and when medication is taken, (Ickowics & 
Meisler, 1997). Nevertheless, Ickowics & Meisler, (1997) caution against regarding it 
as a panacea. Such caution appears warranted, studies using this system, (Bangsberg et 
al., 1998, cited in Levine, 1998) cite 100% adherence according to MEMS, (as 
compared with 92% based on 3 day self-report, and 80% based on random pill counts). 
The authors commented that the full compliance recorded using the MEMS method 
probably reflected the fact that participants reported emptying out all the medications 
needed for the day at one time, thus defeating the object of accurate assessment of 
dosage times. 
One disadvantage to both pill counts and electronic adherence measurement 
systems, rarely discussed in the literature, is the impact it may have on doctor patient 
relationships, in its implicit message that the patients' word cannot be trusted. 
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Ickowics & Meisler, (1997) remark that "drug levels (e.g. serum or urine drug assays) 
and the use of inert biological markers (e.g. digoxin, phenobarbitone), are considered 
more objective measures of adherence, but are unavailable for some drugs and may be 
distorted by the ingestion of medication just prior to a medical visit. (i.e. "white coat 
compliance")" (Ickowics & Meisler, 1997, p. 389). In one study, (Eldred et al. 1998) 
incorporating urine testing to verify the self-report measure only 79% of patients 
reporting adherence had detectable drug levels. 
A few studies take clinical markers, such as the achievement of an undetectable 
viral load as their outcome measures, (Graham, Beeler, Sension, & Renae, 1998). 
Clearly, adherence is important because of its demonstrated relationship with clinical 
outcomes. However, the two are not synonymous, and other factors mediate this 
relationship. One cannot assume that achievement of an undetectable viral load 
necessarily indicates adherence, nor that failure to achieve this goal is attributable to 
non-adherence. 
Reviewing the methods used to assess adherence, Ley, (1988) concludes, 
"patient report correlates reasonably well with other methods of assessment, the 
average correlation being about 0.47. The poorest method seems to be clinician's 
estimate which has an average correlation of about 0.21 with other methods. 
Clinicians are also poor estimators offuture compliance by their patients, (Sackett, 
1979) " (Ley, 1988, p. 281). 
Writing in the Cambridge Handbook of Psychology, Health and Medicine, he 
points to the promise shown by standardised self-report questionnaire measures. 
However, it is fair to say that self-report measures may still overestimate adherence. 
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People may over report adherence because they forget episodes of non-adherence. they 
misunderstand medical advice and do not realise they are nonadherent, as well as 
because of deliberate deception. 
It appears that the reporting of non-adherence is facilitated by the use of 
researchers independent from the clinicians responsible for medical care, and explicit 
that information will not be disclosed to these clinicians (Myers & Midence. 1998). 
It has also been established that the more precise the question. the more accurate 
the response. Behaviour or medication specific adherence measures detect higher rates 
of non-adherence than general ones. (DiMatteo & DiNicola. 1982). 
1.4 Adherence in Conditions Other than HIV 
Studies of adherence in other conditions have established wide variation in adherence 
rates depending on the characteristics of the condition. It is worth noting that 6 - 20% of 
patients fail even to redeem their prescriptions, (Begg, 1984, Berradon et al. 1993. 
Rashid, 1982, and Waters, Gould, & Lunn, 1976, cited in Giuffrida & Torgerson, 1997). 
Adherence is conventionally defined as following the prescribed medical regimen 80% 
or more of the time, (Mehta et al. 1997). The highest rates of adherence (about 80%) 
are found in those with acute symptoms, (such as pain) who are required to follow short 
term (1 0 day) treatments, (DiMatteo, Hays, & Sherbourne, 1992, Sherbourne, Hays, 
Ordway, DiMatteo, & Kravitz, 1992). These rates drop to about 50% in those with 
chronic conditions. Asymptomatic chronic conditions have the lowest rates of all, 
especially where lifestyle changes are involved. We also know that there is an inverse 
relationship between the number of medications prescribed and adherence, (Brand, 
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Smith & Brand, 1997, Clinite & Kabat, 1969, Davis & Eichhorn, 1963, Francis, Korsch 
& Morris, 1969, Hemminki, & Heikkila, 1975, all cited in DiMatteo & DiNicola, 1982). 
The beneficial effects of adherence appear to be greater than those solely 
attributable to the drug. An article by Horwitz and Horwitz (1993) reports intriguing 
findings from a number of well controlled randomised double blind trials in which 
adherence is associated with positive clinical outcomes, even when the treatment is a 
placebo. These findings could not be accounted for by disease severity, stress, 
psychological characteristics, or high risk health behaviours, such as smoking. 
Epstein & Cluss, (1982) speculate about the presence of a third variable to 
account for these effects. They suggest that adherent patients may lead more organised 
and healthy lifestyles, including exercise and healthier diet. Furthermore, they also 
argue that "the act of adhering to a treatment regimen, which allows for a person to 
meet a well defined goal daily, may enhance feelings of well being and reduce 
psychological side-effects of a chronic disease" (Epstein & Cluss, 1982, p.968). For 
well being, one could surely read self-efficacy. 
Most of the research into adherence in chronic conditions has been conducted in 
populations with diabetes, hypertension, and cancer. These conditions typically require 
a protracted process of behavioural change including dietary control and the adoption 
and implementation of exercise programmes. Much of the medical management of the 
condition must therefore be ceded to the patient. This requires shared responsibility and 
collaboration between patient and practitioner. 
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One study, (Kavanagh, Gooley, & Wilson, 1993) examining the relationship between 
self-efficacy and adherence in diabetes, used multiple self-report and objective 
adherence measures. The use of a prospective design allowed them to include baseline 
measures of adherence. Their results demonstrated that self-efficacy was a significant 
predictor of adherence eight weeks later, even after the baseline levels of adherence 
were included in the regression analysis. The authors remark that "self-efficacy 
judgements allow the person to assess a wide range of information they consider was 
relevant to their past adherence and to predict changes in the situation, in their skills or 
in their effort that may be related to their adherence in the future. (Kavanagh et al. 
1993, p. 520). 
Adherence researchers have tended to confine themselves to consideration of 
one of the following: patient characteristics, (sociodemographic variables, psychosocial 
factors such as, beliefs, coping, and social support), disease related variables (such as 
symptomatology), characteristics of the treatment regimen, (duration, complexity, side-
effects), physician characteristics Gob satisfaction), the patient I provider relationship 
(affective tone, communication style, overall satisfaction levels) features of the clinical 
setting, (transport, childcare, confidentiality). DiMatteo and his colleagues in California 
have devoted their energies to the mapping of this particular territory. Their 
development of measures for use across different clinical populations, has facilitated the 
evaluation ofmutivariate theoretical models. For the large-scale Medical Outcomes 
Study (MOS) (DiMatteo, Hays, Gritz, Bastani, Crane, Elashoff, Ganz, Heber, 
McCarthy, & Marcus, 1993) they designed the Adherence Determinants Questionnaire, 
(ADQ), general adherence questionnaire, and some measures of adherence to specific 
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treatment plan components, such as diet and exercise. These self-report measures were 
used alongside objective adherence measures, to investigate the stability of both general 
and specific adherence over a two year period with patients with heart disease, diabetes 
and hypertension. The correlation between general adherence at baseline and at the end 
of the study was .40. Specific adherence was more variable, with a test retest 
correlation of .32. The disease specific correlations were higher (diabetes specific .66, 
heart disease specific, .55, hypertension specific, .56, (DiMatteo et al. 1992). 
Intriguingly, they reported that "general adherence tended to improve over time, 
whereas adherence to certain specific behaviours (medication! diet) became worse and 
adherence to exercise did not change. "(DiMatteo, Sherbourne, Hays, Ordway, Kravitz, 
McGlyn, Kaplan, & Rogers, 1993, p. 99). 
In this study, (DiMatteo, Sherbourne, Hays, Ordway, Kravitz, McGlyn, Kaplan, 
& Rogers, 1993, DiMatteo, Hays, Gritz, Bastani, Crane, Elashoff, Ganz, Heber, 
McCarthy, & Marcus, 1993, Sherbourne et al.1992) the researchers assessed the relative 
weight of five factors associated with adherence in previous research, 1) past adherence 
levels, 2) health perception, 3) psychological factors such as coping style, 4) the 
presence of supports, (including social support) and the absence of barriers to carry out 
the prescribed behaviour, and 5) patient satisfaction with the practitioner patient 
relationship. 
The strongest predictor of adherence two years later was the baseline adherence 
level. The next most powerful predictor of non-adherence was avoidance coping, (e.g. 
made self feel better by eating, smoking, or drinking). The authors also cite earlier work 
by Croog, Shapiro, & Levine, (1971, cited in Sherbourne et al. 1992) linking denial 
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coping with long tenn non-adherence. Interestingly, Sherbourne et al. (1992) did not 
find an association between active coping and adherence. 
Health related distress, (frustration and despair) was also related to non-
adherence which the authors speculate might be related to perceived inefficacy to 
improve their health. 
Quality but not quantity of social support was positively related to adherence, 
and a clear relationship between age and adherence was found, with younger patients 
consistently less adherent. 
Satisfaction with the financial and relationship aspects of medical care provision 
was also predictive of adherence. The relationship between patient and medical team has 
proved to be a crucial one. Early work in diabetes established the significant role this 
interaction plays in patient adherence. A high degree of adherence is required to 
manage this condition, and the procedures involved are aversive to most patients. 
Patients are fearful of criticism from medical staff. Amir, Rabin, & Galatzer (1990) 
argued that a range of specific cognitive and behavioural social skills are needed for 
patients to negotiate such interactions successfully. They hypothesised that 
assertiveness skills would be positively related to adherence. To test this, they designed 
a study which found some support for this proposition, although the direction of 
causality cannot be established. 
A more thorough investigation has been conducted into the influence of 
physician characteristics as part of the MOS outcomes study referred to earlier, 
(DiMatteo, Sherbourne, Hays, Ordway, Kravitz, McGlyn, Kaplan, & Rogers, 1993). 
This found that the level of physician job satisfaction was associated with general 
14 
Introduction 
adherence two years later. Similarly, "medication adherence was better amongJhe 
patients of physicians who had busier practices that is who saw more patients per 
week" (DiMatteo, Sherbourne, Hays, Ordway, Kravitz, McGlyn, Kaplan, & Rogers, 
1993, p. 99) The authors reflect that this may be a function of their popularity, or, 
possibly that they met their patients more often in order to monitor their adherence, a 
practice widely assumed to improve it (Haynes et aI., 1979, Meichenbaum & Turk, 
1987). Certainly, the doctors in that study who made definite follow up appointments 
had higher rates of patient medication adherence. Another significant finding to emerge 
was that doctors reporting greater willingness to answer patients' questions had patients 
who were more adherent to their exercise programmes. These results serve as salutary 
reminders of the degree of influence by healthcare staff on adherence. 
Apart from the adverse effects on individual patients' heath, non-adherence 
incurs other costs. Ley, (1988) cites a 1979 estimate that non-adherence to the ten most 
commonly prescribed drugs would run to between $400-800,000,000. Clearly, twenty 
years later, one might assume that the sum would be substantially greater. 
1.5 Adherence in HIV 
The new antiretroviral therapies require 90-100% adherence to maintain suppression of 
viral replication (Gulick et aI., 1996, Myers, 1996, both cited in Mehta et al. 1997). 
HIV is a chronic disease, which is commonly asymptomatic for up to ten years. 
However, like many chronic conditions, its progression can be punctuated by episodes 
of symptomatic infection. It would seem plausible to expect adherence levels to 
fluctuate with greater adherence during symptomatic periods. Studies of patients with 
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HIV on AZT monotherapy found adherence rates of 60-88% with adherence defined as 
taking over 80% of medication, (Broers, 1994, Samet et aI., 1992, Samuels et ai. 1990, 
cited in Eldred et ai. 1997). Despite the improved prognosis with combination 
therapies, adherence rates appear similar, (Gallant & Block, 1998). As yet, the most 
recent research is only available in abstract form, which makes the findings slightly 
more difficult to interpret. There is some evidence for longitudinal changes in adherence 
which appears adherence greatest at the start of treatment. Gallant and Block, (1988), 
found an inverse relationship between adherence and duration of treatment. Patients 
who had been taking their antiretroviral regimen between two months and a year 
reported an average of 6.2 days of "drug holidays", days in which they stopped taking 
their medication completely. This compares with an average of 14.4 days "drug 
holiday" in those taking medication for over 25 months. 
Patient Characteristics 
Sociodemographic Variables 
The relationship between sociodemographic variables and adherence in HIV has been 
well researched without any dramatic findings. In one prospective longitudinal study, 
age and adherence were unrelated, (Singh, Squier & Hayes, 1994, cited in Mehta et al. 
1997). However, Klosinski & Brooks, (1997) found those under 34 were less adherent. 
This is particular cause for concern since most new diagnoses occur in this age group. 
The evidence as regards sex differences is inconclusive as yet, although there is 
some evidence that men are less adherent than women, (Daniel, Rene & Daniels, 1994 
cited in Mehta et al. 1997). Sexual orientation has also been investigated, although in 
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only one study. Using a rather crude measure of adherence/ non-adherence (whether 
participants reported taking their medications every day over the previous week), 
Klosinski & Brooks, (1997) found 71 % of heterosexuals were adherent as compared 
with 62% of homosexual and 64% of bisexual participants. 
More support has been found for a relationship between adherence and 
socioeconomic status, and related factors such as poor housing, (Daniel et al. 1994, cited 
in Mehta et al. 1997) homelessness, (Bangsburg, 1997 cited in Scherer, 1998) low 
income, (Klosinski & Brooks, 1977) and low educational level, (Daniel et al. 1994, 
cited in Mehta et al. 1997). Ickovics & Meisler, (1997) incorporate these in a more 
general category of "extreme adversity" which includes a number of other variables 
known to be related to adherence, unemployment, homelessness, incarceration, being 
the victim of a violent crime and hospitalisation for mental illness or substance abuse, 
(Broers, 1994, Morse et al. 1995, cited in Ickovics & Meisler, 1997). It is not hard to 
understand how, under such conditions, other issues may take priority. 
The relationship between employment status and adherence is not as 
straightforward as it might at first appear. Unemployment is a risk factor, (Ickovics & 
Meisler, 1997), but other research, (Chesney, 1997) found working outside the home for 
pay was associated with non-adherence. This would suggest that there might be issues 
around fitting pill taking into a work schedule, and also that people might experience 
difficulties finding private space or taking their medications in public, (Eldred et al. 
1997). 
However, even when controlling for these variables, race remains a significant 
predictor of adherence. Ickovics & Meisler (1997) found the highest rates of adherence 
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(defined as having taken medications every day over the past week), amongst the 
Latino sample (72%). This compares with 61% of white participants, Only half the 
black sample met this adherence criteria. 
Psychosocial/Behavioural Characteristics 
One of the most well established risk factors for non-adherence is the presence of a 
psychiatric illness, especially depression, (Broers et al. 1994, cited in Ickovics & 
Meisler, 1997, Singh et al. 1996). This is the more significant given that between 17 
and 30% of people with HIV are depressed, (Fernandez et al. 1989, cited in Mehta et 
aI.1997). Conversely those reporting a satisfactory emotional life also report higher 
rates of adherence, (Hollander, Agnoletto, Calvi, Cargnel, Carosi, Delia, Filippini, 
Mazzotta, Liberati, Spinasanti, Cazzullo, Clerici, & Martini, 1998). 
Current substance use is another major vulnerability factor, (Hollander et 
al.1998, Singh et al. 1996, and Broers et al. 1994, cited in Ickovics & Meisler, 1997). 
Similarly, Chesney & Ickovics, (1997) found an alcohol intake of over 17 drinks per 
month related to non-adherence. Substance use may be considered a coping strategy, 
(normally a maladaptive one when used long term). Other aspects of coping style have 
been found to be related to adherence, (Singh et al. 1996). Specifically, Singh et al. 
(1996) found adaptive coping was positively associated with adherence. 
The evidence as regards social support is inconclusive as yet, (Singh et al. 1996). 
Some studies have found adherence positively related to contact with other seropositive 
people, (Hollander et al. 1988) or the presence of family, (Eldred et al. 1998). In 
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clinical trials, greatest adherence is reported by those with most social support, (Ickovics 
& Meisler, 1997). 
Attitudes and Beliefs 
An increasing body of research demonstrates the importance of cognitive factors such as 
attitudes and beliefs. Much of it has been conducted within the framework of the health 
belief model. As one might expect, those who see their drugs as having little benefit are 
less likely to adhere, Fernandez and Ruiz, (1989, cited in Mehta et al. 1997). The 
perception of HIV itself is important too, (Samet et al. 1992, cited in Eldred et al. 1997). 
The perceived severity of HIV and their perceived susceptibility to opportunistic 
infections are also related to adherence. Concern about taking medications in public has 
already been mentioned, (lckovics & Meisler, 1997). 
More relevant to this study are the findings about perceived self-efficacy. Thus 
far only two studies have considered the role of self-efficacy within adherence to 
treatment in HIV (Eldred et al. 1997, Durvasula et al. 1988). American research (Eldred 
et al.1997) examined the relationship between perceived self-efficacy and adherence to 
antiretroviral monotherapy. This identified a significant correlation between self-
efficacy expectations and adherence (OR=I.57; 95% CIl.13, 2.17). Another study 
explored this relationship in HIV positive women. While the numbers of women 
infected with HIV are growing, (CDC, 1997, cited in Durvasula et al.1988) men remain 
by far the largest group affected. 
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Disease Related Factors 
Health Status 
There is some evidence that health status is related to adherence, although the 
relationship is not an uncomplicated one. One of the few studies specifically 
investigating the impact of disease related factors on adherence in HIV found patients 
with lower CD4 cell counts were less adherent (Meisler, Ickovics, Walesky, Feller, 
Skowronski, & Friedland, 1993, cited in Ickovics & Meisler, 1997). They suggested 
that adherence may decline with disease progression although this would surely need to 
be cognitively mediated. They attribute this to a combination of "physical and 
cognitive limitations, loss of belief in the efficacy of treatment and loss of social support 
with advanced disease" (p. 388). 
Singh et al. (1996) found people with experience of an opportunistic infection 
were more adherent. The authors argue, convincingly, that infections heighten 
perception of susceptibility to future infections. Asymptomatic people may consider 
themselves less vulnerable and be correspondingly less motivated in their adherence. 
"An opportunistic infection or the presence of physical symptoms probably heightens 
the perceived severity of the illness and therefore the motivation of the patient to comply 
with therapy" (Singh et al.1996, p. 267). 
Although this is intuitively plausible, it ought to mean that adherence is 
positively correlated with the presence of pain. Klosinski & Brooks', (1997) research 
suggests that the relationship is less simple. Using their dichotomous classification 
system, (adherent / nonadherent), 40% of people reporting moderate pain were non-
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adherent as compared with 33% of people reporting no pain, and 31 % reporting extreme 
pain. 
Other findings from this study suggest that it may be change in health status that 
is the crucial variable. Those reporting an improvement in their health compared with a 
year previously reported significantly greater adherence than those for whom there was 
no change, or who experienced deterioration. 
Medication Related Factors 
The relationship between adherence and the length of time on medications has already 
been observed, at least as regards drug holidays. The longer the time spent on 
medication, the more days are taken as "drug holidays". 
It is clear that there is an inverse relationship between adherence and the number 
of medications taken, although it may be a function of the complexity of the regimen, 
(Ickovics & Meisler, 1997). The number of medications may be less important than 
dose frequency. 
As one might expect, adherence also varies according to the type of medication, 
(Nakashima, 1988). Side-effects account for some of this variance. Anaemia, 
leukopenia and diarrhoea are known to decrease adherence, (Broers, Morabia, Hirschel, 
1994, Samet, Libman, Steger, et al. 1992, Samuels, Hendrix, Hilton, Marantz, Sloan, 
Small, 1990, Easterbrook, Keruly, Creagh-Kirk, Richman, Chaisson, & Moore, 1991, all 
cited in Mehta et al. 1997). 
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Patient Provider Relationship 
Healthcare practitioner-patient communication 
One European study, (Hollander et al. 1988) found satisfaction with their physician was 
significantly correlated with adherence, (defined as less than two occasions of non-
adherence over the previous two months). 
Relationship issues may be particularly important with HIV positive injecting drug 
users. One study, (Broers, Morabia, Hirschel, 1994, and Gerbert, Maguire & Bleeker, 
1991, cited in Mehta et al. 1997) suggested that physicians may have negative attitudes 
to injecting drug users and therefore make less effort to recommend combination 
therapy. 
Interventions Targeting Adherence in HIV 
Given the well established importance of adherence, one might expect a proliferation of 
intervention trials designed to increase adherence, but few research papers have been 
published as yet. Moreover, there seems to be a notable absence of psychological 
involvement in the four studies reported thus far, with the march stolen by pharmacists 
and occupational therapists. Unfortunately, only cursory information is available about 
these projects, three of which were presented at the 12th World Aids Conference in 
Geneva, and are currently only available in abstract form. 
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1.6.1 Health Belief Model 
Introduction 
These findings have been considered within the theoretical framework of the Health 
Belief Model, (Rosenstock, 1966, Becker & Rosenstock, 1987, cited in Ogden, 1996) 
and the Theory of Reasoned Action (Ajzen & Fishbein, 1980, cited in DiMatteo et al. 
1992). The Health Belief Model evolved from Social Cognitive Theory, (Bandura, 
1977, 1986) which assumes that behaviour is determined by expectancies and 
incentives. Expectancies refer to beliefs about the probability that specific actions will 
produce particular outcomes or consequences. The subjective value or importance of 
those consequences are considered incentives. The value attached to health accounts for 
the performance of particular health behaviours, especially the adoption of disease 
prevention measures, and attendance for routine screening tests (in the absence of 
symptomatology) which the model was originally designed to predict. Health 
motivation determines behaviour in the context of the degree of perceived threat posed 
by the disease and the relative weighting of the risks and benefits associated with the 
recommended behaviour(s). The estimation of perceived threat is derived from an 
assessment ofthe perceived severity of the particular condition and the individuals 
perceived susceptibility to it. 
The model generated a large amount of research investigating a wide range of 
health behaviours. Reviewing these studies, Home & Weinman, (1998), conclude that 
the model is most useful as a predictor of preventative behaviours. They cite the meta-
analysis conducted by Zimmerman & Vemberg, (1994, cited in Home & Weinman, 
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1998) finding that the components of the Health Belief Model accounted for an average 
of24% of the variance in preventative health behaviours. 
They discuss a number of the model's limitations. Firstly, by neglecting the 
formation of behavioural intentions, it fails to specify the mechanisms whereby health 
beliefs determine behaviour. Secondly, the influence of social factors, such as the desire 
for others' approval remains undefined. Moreover this model may account for decisions 
about isolated events such as screening, but is unlikely to explain the complicated 
processes involved in maintaining health behaviours, such as adherence in chronic 
conditions. 
Figure 1. The Health Belief Model (adapted from Horne & Weinman, 1998) 
Demographic 
Variables 
class, 
gender, 
age, etc. Health motivation 
Psychological Perceived benefits Characteristics II----+L_~~::!Y~~~~ _ _.l 
personality 
Perceived barriers 
1.6.2 Theory of Reasoned Action 
Action 
Ajzen & Fishbein, (1980, cited in DiMatteo et al. 1992) developed a theory which 
addresses two of the weaknesses of the Health Belief Model, by incorporating the 
influence of social factors, (subjective norms) and the central importance of behavioural 
intentions in predicting behaviour. The model suggests that volitional action is best 
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predicted by the intention to perform a particular behaviour. Behavioural intentions are 
formed on the basis of an individuals attitude towards the behaviour, their perception of 
social norms regarding it, and the value they place on the opinions of significant others. 
One might for example, be highly motivated to adopt or maintain a behaviour because it 
is approved or deplored by a significant other(s). Attitudes towards behaviours are a 
combination of beliefs about the outcomes of the particular behaviour and an evaluation 
of the outcome. For example, one might have doubts about the relationship between 
smoking and cancer, but believe the benefits of giving up outweighed by the costs in 
terms of the difficulty and the loss of a strategy for coping with stress. 
1.6.3 Perceived Self-Efficacy 
Another strand of theoretical research has explored the role of self-efficacy in health 
behaviour, including adherence to medical recommendations. Self-efficacy theory has 
its origins in Social Learning Theory, (Bandura, 1977, cited in Kavanagh et al. 1993). 
The theory "postulates that people's perceptions of their capabilities affect how they 
behave, their level of motivation, their thought patterns and their emotional reactions in 
taxing situations" (O'Leary, 1985, p. 437). Perceived self-efficacy refers to people's 
jUdgements of their ability to perform particular behaviours to a specified level. Beliefs 
about the outcomes of the behaviour are termed outcome expectancies, and are 
considered conceptually distinct although the validity of this distinction has been 
questioned, (Eastman & Marzillier, 1984). 
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Efficacy expectations determine whether or not people will embark on a program of 
health related behaviour (diet, exercise, medication adherence) and affects the degree of 
commitment and persistence they display towards it. "Adherence to difficult medical 
regimens by patients might thus be more consistent and longer lasting in those patients 
whose beliefs in their abilities to affect their health are strong" (O'Leary, 1985, p.438). 
Studies exploring the contribution made by efficacy expectations have 
demonstrated its utility in predicting sustained change in behaviours as diverse as 
smoking, pain management, diabetic dietary control, fluid restriction in renal failure, 
(Rosenbaum & Ben Ari-Smira, 1986, Schneider, Friend, & Whitaker, 1991) and alcohol 
use, (Kavanagh et al.I993). 
Bandura (1997) argues that perceived self-efficacy affects mood as well as 
behaviour. "Mood and perceived efficacy can influence each other bidirectionally. 
Perceived inefficacy breeds depression. Despondent mood diminishes perceived 
efficacy: positive mood enhances it, (Kavanagh & Bower, 1985). "(Bandura, 1997, 
p.160). In his earlier work, Bandura, (1988) provided an account of the processes 
whereby perceived self-efficacy reduces vulnerability to depression, (Kavanagh et al. 
1992, cited in Schwarzer, 1992). Evidence to support this thesis has been found from a 
study of patients with multiple sclerosis or spinal cord injury (Shnek, Foley, LaRocca, 
Gordon, Deluca, Schwartzman, Halper, Lennox, & Irvine, 1997). 
Perceived self-efficacy also appears to affect the immune system. Bandura, 
(1997) cites epidemiological and correlational research demonstrating that lack of self-
efficacy increases susceptibility to infection, contributes to the development of physical 
disorders and accelerates the rate of disease progression, (Peterson & Stunkard, 1989, 
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Schneiderman, McCabe & Baum, 1992, both cited in Bandura, 1997). Experimental 
studies have established that exposure to stressors which one has the ability to control 
has no adverse effects on the immune system, while exposure without control impairs it. 
Most fascinating of all, the process of self-efficacy attainment and mastery over phobic 
stressors appears to actively enhance immune functioning, (Weidenfeld, Bandura, 
Levine, O'Leary, Brown, & Raska, 1990). Moreover, these immunoenhancing effects 
persist such that Bandura, (1997) suggests they may serve a protective function in later 
times of stress. 
As early as 1977, Bandura's research conclusively established that self-efficacy 
could be experimentally manipulated. Later work has demonstrated that clinical 
interventions can increase self-efficacy for changing health related behaviours such as 
smoking, (Condiotte & Lichtenstein, 1981, cited in Eldred et al. 1997) contraceptive 
use, (Gilchrist & Schinke, 1983, cited in Eldred et al. 1997) and exercise, (Ewart, 
Taylor, Reese & Debusk, 1984, cited in Eldred et al. 1997). Moreover, in these studies, 
increases in self-efficacy was related to subsequent changes in these behaviours. The 
clinical applications of self-efficacy acquisition have been extended to include pain 
management, the treatment of eating disorders, cardiac rehabilitation, (O'Leary, 1985) 
and hemodialysis, (Rosenbaum & Ben-Arl Smira, 1986). 
1.6.4 Criticisms of Perceived Self-efficacy 
Borkovec, (1978, cited in Kavanagh et al. 1993) has suggested that it is people's skills, 
not their self-efficacy which determines behaviour. Past performance levels provide a 
measure of someone' s range and level of skill attainment (although these will also have 
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been influenced by self-efficacy expectations). According to this view, cogently 
expressed by Eastman & Marzillier, (1984) self-efficacy expectations may merely 
reflect accurate predictions of future performance based on assessment of past 
behaviour. As a result, much self-efficacy research has examined the relative 
contribution of performance and self-efficacy as predictors of subsequent behaviour. 
There is now an increasing body of research to suggest that self-efficacy is a better 
predictor than performance, (Condiotte & Lichtenstein, 1981, Kavanagh & Wilson, 
1989, Kavanagh et al. 1993, Sitharthan & Kavanagh, 1990, Yusaf & Kavanagh, 1989, 
all cited in Kavanagh, 1993). 
More persuasive still, experiments have been designed to test the proposition 
that self-efficacy is not a cause but a correlate of behaviour change. Litt's (1988) work 
exploring self-efficacy for cold-pressor pain tolerance tasks established that self-efficacy 
change predicted change in performance better than past performance or actual 
performance changes. As one might expect, this relationship is strongest where people 
have some experience of the task. 
His experimental design also allowed him to test Bandura's (1982) proposition 
that people with high self-efficacy are likely to choose to exercise control where 
possible, while people with low self-efficacy are not, and indeed may experience 
distress and anxiety if forced to do so. The results of the study largely supported these 
hypotheses. 
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1.6.5 The Theory of Planned Behaviour 
Such findings led Ajzen and colleagues (Ajzen, 1985, 1988, Ajzen & Madden, 1986, 
cited in Ogden, 1996) to modify the theory of reasoned action to incorporate other 
factors, renaming the updated version the Theory of Planned Behaviour. This 
incorporated an additional component termed perceived behavioural control, (the extent 
to which one considers a particular behaviour within one's control). The perception of 
control encompasses evaluation of the availability of internal and external resources, 
such as skills, abilities, and information, and the presence of environmental factors, 
help and hindrances. There are clearly similarities to the concept of perceived self-
efficacy, (although it is measured by asking people to rate the relative ease/difficulty of 
particular behaviours, without the most crucial aspect for measuring self-efficacy, 
asking how easy/difficult the behaviour is for them). 
The addition of perceived behavioural control improved the predictive power of 
the model which has been used to successfully predict a wide range of health 
behaviours. However, it has been criticised (Schwarzer, 1992) for underestimating the 
role of self-efficacy particularly as it affects the maintenance of health behaviours (as 
opposed to their initiation). 
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Figure 2. The Theory of Planned Behaviour (adapted from Home & Weinman, 1998) 
Demographic 
Variables 
age, sex, 
occupation, 
socioeconomic 
status, religion, 
education, 
Personality 
traits 
extraversion 
conscientious-
ness 
neuroticism 
openness 
Belief Evaluation 
X of 
Outcomes Outcomes 
Motivation 
Attitudes towards 
behaviour 
Normative 
Beliefs X to comply 1-----+1 
Perceived 
Likelihood of X 
Occurrence 
Perceived 
Facilitating! 
Inhibiting 
Power 
The Theories of Reasoned Action and Planned Behaviour have been used extensively to 
investigate behaviours from smoking cessation to the initiation of exercise regimes or 
condom use. They have also been used to successfully predict adherence to medication 
for urinary tract infections, (Reid & Christensen, 1988, cited in Home & 
Weinman,1998). 
Nevertheless, while intention emerges as a strong predictor, it is common 
knowledge that intention alone does not predict behaviour. Empirical tests of the 
predictive power of this model have established that "Health beliefs and motivation for 
health correlate better with behavioural intentions than with adherence behaviours, 
although the former affects the latter as noted above ". (DiMatteo, Hays, Gritz, Bastani, 
Crane, Elashoff, Ganz, Heber, McCarthy & Marcus, 1993, p.l 02). 
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1.6.6 The Health Action Process Approach 
Schwarzer's Health Action Process Approach (Schwarzer, 1992) conceptualises the 
initiation and maintenance of health behaviours as a process with two distinct phases, a 
motivational stage, followed by an action stage. People are seen as evaluating threats to 
their health in terms of their own individual vulnerability to any condition and 
consideration of its severity. These are then considered in the context of their 
expectations about outcomes. Self-efficacy expectations will inform outcome 
expectations, and thus intentions and plans for action. Perceived resources (such as 
social support) and barriers (financial constraints) further affect the volitional process. 
Figure 3. The Health Action Process Approach (adapted from Schwarzer, 1992) 
Outcome 
expectancies 
Threat 
Severity I 
Vulnerability 
Self-efficacy 
Volitional Process 
Action Plans 
barriers, 
resources, 
social 
support 
Actual 
barriers, 
resources, 
social support 
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1.6 7 Integrating Perceived Self-Efficacy and the Transactional Model of Stress and 
Coping 
It will be apparent that the Health Action Process Approach shares some features with 
Folkman & Lazarus' (1984) Stress and Coping model. The evaluation ofthreat in terms 
of individual vulnerability and severity constitutes primary appraisal. Consideration of 
coping resources can be conceptualised as a function of secondary appraisal. 
1.6.8 The Transactional Model of Stress and Coping 
Coping has been divided into emotion focused coping and problem focused coping. 
Appraisal evaluates the stressor as changeable or unchangeable. Where a stressor is 
accurately appraised as changeable, problem focused strategies are appropriate, but not 
if it is unchangeable, when emotion focused coping is required. Most stressors have 
both changeable and unchangeable aspects. Dysfunctional coping refers to a mismatch 
between the changeability of the stressor and the coping strategy employed. 
An HIV diagnosis clearly constitutes a major stressor, as is the requirement that one 
adhere to a rigorous pill taking schedule on an indefinite basis. As an unchangeable 
stressor, the diagnosis itself requires emotion focused coping, while adherence to 
medication is problem focused coping. 
More recently it has been suggested (Carver et al. 1989, cited in Kennedy et al. 
1995) that the distinctions between emotion and problem focused coping strategies are 
overly simplistic, and ignore the complexities of the coping process. 
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1.6.9 Coping and Perceived Self-Efficacy 
Gattuso, Litt, & Fitzgerald (1992) have attempted to explore the relationship between 
coping and perceived self-efficacy. These researchers used the coping trait 
classification proposed by Shipley, Butt, & Horwitz, (1979, cited in Gattuso et al. 
1992). This divides people into monitors (information seekers) and blunters, 
(information avoiders). Shipley et aI. (1979, cited in Gattuso et al. 1992) advanced a 
congruency hypothesis arguing that information will be beneficial for monitors and may 
be detrimental for blunters. Gattuso et aI. (1992) devised a self-efficacy enhancement 
intervention for men undergoing endoscopy procedures and compared monitors and 
blunters under four conditions: 1) self-efficacy intervention, 2) relaxation, 3) procedural 
information, 4) control group. Post-intervention self-efficacy predicted behavioural and 
physiological measures of distress during the procedure. Contrary to their predictions, 
although monitors performed best after the self-efficacy intervention, monitors did as 
well with self-efficacy as in any of the other conditions. 
1.6.10 Coping in Chronic Conditions 
Studies of coping in people with chronic conditions have established that there is 
considerable stability in the use of coping strategies over time, and some coping 
strategies are consistently associated with better psychological outcomes. On the basis 
of empirical evidence from a prospective study of coping in patients with spinal injury, 
Kennedy et al. (in press) concluded that adaptive coping was associated with the use of 
acceptance, active coping, positive reinterpretation and growth. Conversely, 
maladaptive coping was associated with behavioural disengagement, lack of acceptance, 
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and alcohol and drug ideation. Similar classifications have been made with HIV 
positive populations. Antoni, (1997) associated maladaptive coping with denial, mental 
disengagement and behavioural disengagement. Acceptance, active coping, positive 
reframing, and planning constituted adaptive coping strategies. 
The relationship between avoidant coping and adherence in chronic conditions 
has already been mentioned, (Sherbourne et al. 1992). 
1.6.11 Coping in HIV 
In addition to the evaluation of interventions designed to increase adaptive coping in 
people with HIV, researchers have applied themselves to identifying the links between 
coping and other physical or psychological health indicators, such as immune 
functioning and depression. Some studies, (lronson et al. 1994, Philips, 1992, cited in 
Mulder, Antoni, Duivenvoorden, Kauffmann, & Goodkin, 1995) have found significant 
relationships between coping strategies and disease progression. Mulder et al. (1995) 
found the use of active coping predicted decreased clinical progression after a year, 
which they suggested might be a product of increased adherence. 
Avoidant coping in HIV on the other hand, has been found to be significantly 
correlated with depression, (Fukunishi, Negishi, Hayashi, Hosaka, Moriya, & 
Matsumoto, 1996). 
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1.6.12 Coping and Perceived Self-efficacy in HIV 
The combination of perceived self-efficacy and choice of coping strategy in the context 
of perceived and real barriers and supports for adherence will determine an individual's 
secondary appraisal. "Expectations of perceived self-efficacy determine whether coping 
behaviour will be initiated, how much effort will be expended, and how long it will be 
sustained in the face of obstacles and aversive experiences" (Bandura, 1977, p.191). 
The construct of coping self-efficacy (self-efficacy for coping with challenges and 
threats) has been investigated more fully in relation to HIV by Chesney, Folkman, & 
Chambers' (1996) work on coping effectiveness training. 
Entitling this construct coping self-efficacy has the merit of defining more 
precisely the area to which the perceived self-efficacy refers, but is rather confusing if 
one wishes to consider the relationship between perceived self-efficacy and differential 
selection of coping strategies. 
One study exploring these constructs separately in HIV (Sharts-Hopko, Regan-
Kubinski, Lincoln, & Heverley, 1996) found perceived self-efficacy was inversely 
associated with measures of psychological distress, and positively associated with 
problem focused coping. 
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1. 7 Rationale 
Adherence to medication regimes is crucial for the treatment of people with HIV and 
prevention of the development of drug resistant viral strains. As yet, little is known 
about the risk factors of non-adherence and research has been empirically driven rather 
than theoretically grounded. Theoretical models permit a more structured analysis of 
the process, allow the development of predictions and indicate possible areas for 
intervention. 
Studies of adherence in other chronic conditions have established the importance 
of perceived self-efficacy in adherence (Kavanagh et al. 1993). Researchers exploring 
this relationship in HIV have confined themselves to HIV positive women, (Durvasula 
et al. 1998) or were conducted when the only treatment available was monotherapy, 
which is much less effective than the new combination therapies. This study attempted 
to investigate the role of perceived self-efficacy in adherence in people with HIV 
including the relationship between perceived self-efficacy and other variables known to 
be associated with adherence. It aimed to address these issues with a UK HIV positive 
popUlation. The Health Action Process Approach was chosen as the theoretical 
framework in which to locate the study because of the central role it assigns to 
perceived self-efficacy and also because of the emphasis given to the maintenance of 
health behaviours. 
36 
Introduction 
1.8 Research Aims 
1. This study aims to investigate the role of self-efficacy in adherence to antiretroviral 
medication in people with HIV. 
2. It will also explore the relationship between self-efficacy and coping strategies. 
3. The relationship between self-efficacy and depression will be examined. 
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1.9 Statement of Hypotheses 
HI. A positive relationship is predicted between perceived self-efficacy and 
adherence to combination drug therapies in HIV. 
H2. An inverse relationship is predicted between self-efficacy and depression. 
H3. Irrespective of depression level, it is predicted that perceived self-efficacy will 
account for a significantly greater proportion of the variance in adherence to 
antiretroviral medications than other variables known to be associated with 
adherence such as age, substance use, AIDS diagnosis, and side-effects. 
H4. A positive relationship is predicted between perceived self-efficacy and 
adaptive coping strategies, such as acceptance, active coping, positive 
reframing, and planning. 
H5. An inverse relationship is predicted between perceived self-efficacy and 
maladaptive coping strategies, such as denial, behavioural disengagement, self-
distraction, and alcohol and substance use. 
H6. Self-efficacy will account for a greater proportion of the variance than other 
Health Belief components of the Health Action Process Approach, 
(interpersonal aspects of care, perceived susceptibility, perceived severity, 
intentions, supports and barriers, and subjective norms). 
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2. Method 
This section outlines the planning and implementation of the study and is subdivided as 
follows: 
• Experimental Design 
• Ethical Approval 
• Participants 
• Measures 
• Treatment of Results 
• Procedure 
• Dissemination of Results 
2.1 Design 
This study employed a cross-sectional within subjects design. All participants 
completing an 283 item questionnaire at one time point. The dependent variables were 
four different measures of adherence: two global measures of adherence to dose times 
and adherence to special instructions, and two composite measures of dose omissions 
and dose delays. The independent variables were measures of perceived self-efficacy, 
coping strategies, depression levels, and a number of demographic, medication, and 
illness-related variables. All participants were given all measures. 
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2.2 Ethical Approval 
Ethical approval for the study was sought and obtained from the East London and City 
Health Authority (hereafter ELCHA) subject to the consent of the consultants clinically 
responsible for patients (see Appendix I). Arrangements for dealing with distress 
elicited or uncovered by the study are outlined below. 
2.3 Participants 
Participants were recruited from HIV positive people attending routine clinic appointments at 
two linked HIV clinics in London, St Bartholomew's Hospital and the Royal London 
Hospital. All participants were volunteers over eighteen years old and taking antiretroviral 
therapies. Critically ill patients, those with severe psychiatric illnesses, and non English 
speakers were not approached for inclusion in the study. 
2.4 Measures 
Measures of demographic information, global and medication specific self-efficacy, 
global and medication specific adherence, mood, coping style, and health beliefs, were 
included. The full questionnaire is shown in Appendix IV. It consisted of the following 
self-report instruments which were selected for their reliability, validity, ease of 
administration and prior use with HIV infected populations and / or people with other 
chronic illnesses. 
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Independent Afeasures 
2.4. I Demographic Iriformation Afeasure 
This measure was derived from a questionnaire designed for a previous study conducted 
within the Royal London Hospitals Infection and Immunity Service, (Hedge & Petrak, 
1998). It covered demographic information such as age, sex, ethnic origin, sexual 
orientation, first language and country of birth, and illness-specific information such as 
date of diagnosis, CD4 count, viral load, and disease status. It also assessed HIV 
antiretroviral medication combinations. 
2.4.2 Afood 
Anxiety and depression levels were assessed by the Hospital Anxiety and Depression 
Scale (HADS) a standardised fourteen item test, (Zigmond & Snaith, 1983) designed to 
provide a state measure of anxiety and depression without contamination by physical 
symptomatology. Each subscale has seven items. Respondents are asked to rate their 
agreement with statements with scores ranging from 0 to 3. Scores of 8-1 0 on each 
scale are taken to indicate possible psychiatric disorder, whilst scores of 11 or above 
suggest probable psychiatric disorder. Internal consistency is high with Cronbach Alpha 
scores of 0.93 and 0.90 for anxiety and depression respectively, (Moorey, Greer, 
Watson, Gorman, Rowden, Tunmore, Robertson, & Bliss, (1991). The measure has 
considerable face validity with respondents finding it easy and acceptable. High 
concurrent validity has also been demonstrated (Zigmond & Snaith, 1983). This 
measure was selected for its reliability, validity, and frequency of use in comparable 
studies in HIV and other chronic illnesses. 
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2.4.3 Coping 
Coping style was measured using a shortened (24 item) version of the COPE (Carver, 
Pozo, Harris, Noriega, Scheir, Robinson, Ketcham, Moffat, & Clark, 1993). This is an 
inventory of coping responses with a range of fifteen conceptually distinct scales. 
Responses assessed by this measure range from aspects of problem-focused coping (e.g. 
active coping, planning) to the use of social support, turning to religion as a coping 
strategy, to positive reframing of the situation, to forms of avoidance coping (e.g. denial, 
behavioural disengagement). Response choices ranged from 1. I have not been doing 
this at all to 4. I have been doing this a lot. Scores for each scale are computed by 
adding the scores for each of the items. 
The original COPE scales were developed from a factor analysis of 60 items. 
The alcohol/drug use and humour scales were developed after the other scales and are 
considered exploratory by the authors. They consider scales 1,2,5, 7, and 8 adaptive 
in situations where active coping yields good outcomes. Scales 3, 4, and 6, are thought 
probably adaptive in these situations. The authors comment that it is less clear what 
strategies would be most adaptive in dealing with uncontrollable aspects of the situation, 
such as the presence of HIV infection. 
Different versions of the instructions mean the COPE can be used as either a 
dispositional measure (how one usually copes with stressful events) or a situational 
measure, (how one copes with specific situations or during a defined time period). In 
the current study the situational version was used, and participants were asked to rate 
their coping responses since diagnosis, (see Appendix IV for the full instructions). 
42 
Method 
Construct validity was tested for the original COPE, by comparing various personality 
traits thought to be associated with particular forms of coping. The active coping, 
planning, positive reinterpretation and growth subscales are positively correlated with 
measures of optimism and self esteem and negatively correlate with trait anxiety. 
Denial and behavioural disengagement displayed the opposite pattern. 
The abbreviated COPE has two items for each scale. The focus of the scales was 
altered slightly in the process such that the positive reinterpretation and growth scale 
became positive reframing (questions tapping growth were excluded). Concentrating on 
and venting of emotions became venting, and mental disengagement became self-
distraction. This shortened version was selected because of concerns about the 
participants' possible fatigue, given the length of the full questionnaire. Levels of 
internal consistency are adequate, (Cronbach's alpha> 0.5) for all the scales (Carver, 
1997). 
2.4.4 Generalised Self-Efficacy 
This was measured using the Generalised Self-Efficacy Scale (GSES) developed by 
Schwarzer and Jerusalem (1993, cited in Schwarzer, 1993). This ten item questionnaire 
"assesses the strength of an individual's belief in his or her own ability to respond to 
novel or difficult situations and to deal with any associated obstacles and setbacks" 
Schwarzer and Jerusalem (1993, cited in Schwarzer, 1993, p. 220). Participants are 
asked to rate their degree of agreement with each statement. Responses range from 1. 
not at all true to 4. exactly true. The scores for each of the ten items are summed to give 
a total score. It should be noted that all the normative data has been collected from 
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German samples. However, high levels of internal consistency have been found in all 
the samples studied, with Cronbach's alphas ranging from 0.82 to 0.93. High test-retest 
reliability and adequate concurrent validity has also been established. 
Factor analyses have been used to assess unidimensionality and a single factor 
solution has been found indicating that the GSES is measuring a unitary concept. 
2.4.5 Medication Specific Self-Efficacy 
Two aspects of Medication Specific Self-Efficacy were measured. 
1. Self-efficacy for adherence to specific medications was assessed by adapting a 
question devised by Durvasula et al.(1998). These authors used an eleven point Likert 
scale which was reduced to a five point scale for the purposes of this study. 
2. Self-efficacy for Medication Specific Problem Solving 
This Was assessed using a question devised by DiMatteo, Hays, Gritz, Bastani, Crane, 
Elashoff, Ganz, Heber, McCarthy, & Marcus, (1993). 
2.4.6 HIV Specific Health Beliefs 
In the absence of a measure designed to test components of the Health Action Process 
Approach, the ADQ (DiMatteo, Hays, Gritz, Bastani, Crane, Elashoff, Ganz, Heber, 
McCarthy, & Marcus, 1993) was selected as measuring the health belief elements, 
namely: 1) perceived severity, 2) perceived vulnerability, 3) outcome expectancies, 
referred to as perceived utility, 4) intention, 5) presence of perceived supports and 
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absence of perceived barriers. This measure does not directly assess social support, but 
assesses the normative influence of significant others. Additional items to measure self-
efficacy were inserted. 
HIV Specific Health Beliefs were measured by adapting the 38 item Adherence 
Determination Questionnaire (DiMatteo, Hays, Gritz, Bastani, Crane, Elashoff, Ganz, 
Heber, McCarthy, & Marcus, 1993) for use with an HIV positive population. The ADQ 
was designed to measure the components of the Health Belief Model. Adequate 
reliability (median alpha reliability. 76) for these components has been established. The 
ADQ Was used as a framework into which questions from other studies of health beliefs 
within HIV positive people were incorporated. Thirty items were included from a study 
by Catt, Stygall, & Catalan, (1995) exploring the acceptance of AZT monotherapy in 
early HIV disease. Also inserted were a further 20 questions from an American study 
by Rossman & Goetz (1998) into adherence to combination therapies. Ten items 
developed by Eldred et al. (1998) to assess perceived self-efficacy for medication 
adherence were also included. Four additional items (assessing the subjective influence 
of doctors and partners) were devised by the author. The modified questionnaire 
consisted of 106 statements to which the participants rated the extent of their agreement 
on a five point Likert scale ranging from 1 = strongly agree to 5= strongly disagree. The 
components measured were Interpersonal Aspects of Care, exploring the relationship 
with health professionals, specifically, Communication, (four items), and Rapport, (five 
items) Intention to Adhere, (seven items), Perceived Susceptibility to Disease 
Progression, (14 items) Perceived Severity of Disease, (11 items) and Perceived Utility 
(Costs/ Benefits of Therapy) (12 items), and the Presence of Perceived Supports and 
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Absence of Perceived Barriers to treatment (12 items). Subjective norms (assessing five 
normative expectations [aspects of the regimen by five sources, doctor, family, friends, 
partner, and relatives, multiplied by the respondents desire to conform to the wishes of 
these normative people: as recommended by Ajzen & Fishbein, 1980, cited in DiMatteo, 
Hays, Gritz, Bastani, Crane, Elashoff, Ganz, Heber, McCarthy, & Marcus, 1993]. Also 
included were 18 items measuring Perceived Self-Efficacy. 
Following DiMatteo et aI. (1993) the influence of each normative target was 
assessed with two statements, ego 1. My relatives think I shouldfollow my treatment 
plan. 2. I want to do what my relatives think I should do about my treatment plan. As 
recommended by Ajzen & Fishbein, (1980, cited in DiMatteo, Hays, Gritz, Bastani, 
Crane, Elashoff, Ganz, Heber, McCarthy, & Marcus, 1993), scores on the two 
statements were multiplied to form a score for each of the five social norm sources: 
doctor, family, friends, partner, and relatives. Responses were recoded according to the 
recommendations of Ajzen & Fishbein, (1980, cited in DiMatteo Hays, Gritz, Bastani, 
Crane, Elashoff, Ganz, Heber, McCarthy, & Marcus, 1993): for Motivation (2.), 
Strongly agree=3, Agree=2, Neither agree nor disagree= 1, Disagree, and Strongly 
Disagree=O; for Normative Belief (No.1), Strongly agree=2, Agree= 1, Neither agree nor 
disagree=O, Disagree=-l, and Strongly Disagree=-2. 
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Dependent Measures 
2.4.7 Treatment Adherence Measures 
Global and medication specific self-reported adherence was assessed using measures 
developed for the study reported earlier, (Hedge & Petrak, 1998). The adherence 
questions encompass three dimensions of adherence, 1. dose timing, 2. dose omissions 
and 3. changes to dosage levels. Participants also indicated what happened on the last 
occasion that their medication taking routine was disrupted. 
2.5 Treatment of Results 
Statistical Analysis 
Participant demographics, psychological indices, and medication adherence levels were 
entered into a database (SPSS 9.0 for Windows). Kolmorgorov-Smimov Goodness of 
Fit tests were performed on the variables under consideration, to investigate whether 
they were normally distributed. A number of variables were found to be non-normally 
distributed in the total sample, non parametric statistics were applied to these variables. 
Multiple and stepwise regression models were used to evaluate factors associated with 
non-adherence. 
2.6 Procedure 
All participants completed the questionnaire, which took approximately 30 - 45 minutes. 
The method of recruitment differed slightly between sites. All participants were 
approached on routine clinic visits, either directly, (at the Royal London Hospital) or 
after referral by their consultant physician, (St Bartholomew's Hospital) and invited to 
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participate in the research study. Those that expressed an interest were then provided 
with further infonnation about the study both orally and in the fonn of an infonnation 
sheet (see Appendix II). They were also offered the opportunity to ask questions about 
the study. Those people who agreed to participate in the study were asked to read and 
sign a consent fonn (see Appendix III). Participants were offered a private room in 
which to complete their questionnaire but some preferred to remain in the waiting room. 
Arrangements were made to cope with possible distress occasioned by participation in 
the study. Questionnaires were completed with the researcher present. Participants were to be 
awaiting an appointment with a clinician with whom such issues would routinely be 
discussed. Should participants became distressed after leaving the clinic, the infonnation 
sheet provided a contact number for those wishing to access psychological support from one 
of the investigators. However, no participant expressed distress and several commented on 
beneficial aspects of participation. For the most part, this entailed feeling the difficulties of 
adherence were being taken seriously, and feeling that their personal experience was valued 
and might contribute to the furtherance of knowledge about adherence. Participants were 
infonned that a summary of the results of the study would be available from the clinic 
reception once the study was completed. 
2.7 Dissemination of results 
A summary of the findings of the study is planned and will be circulated to the St 
Bartholomew'S and the Royal London Infection and Immunity Service. Copies will 
also be available at the clinic reception for participants and other interested service 
users. 
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3. Results 
This section will outline the results obtained which are presented in the following order: 
• sample size 
• descriptive data for the dependent and independent variables 
• investigation of the hypotheses. 
3.1 Sample size. 
52 participants completed questionnaires, although many people omitted some items. 
3.2 Descriptive data for the dependent and independent variables 
Age 
The mean age of participants was 38.29 years, with ages ranging from 22-69, (SD 9.59). 
Sixteen people, (34 %) were under 34 years old, only one participant was under 25. One 
Participant (1.9%) did not provide information about their age. 
Sex 
Over three quarters of respondents, (78.8%) were male and 19.2% female. One 
respondent (1.9%) did not identify their sex. 
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Cultural Background 
Over half the sample, (53.8 %) identified as of white, UK backgrounds. Six people 
(1l.5%) described themselves as of European origin, and one person, (l.9%) as Jewish. 
Eleven people (21.1 %) identified as black, (including people of Caribbean and African 
descent). Two people (3.8%) reported Chinese backgrounds and a further two described 
themselves as Latin American. One person, (1.9%) identified as Vietnamese. 
Language 
Almost three quarters, (73.1 %) of participants described English as their native 
language. Other first languages included Amharic, Chichewa, Chinese, French, Luo, 
Portugese, Somali, and Spanish. 
Current Relationships 
Over half the sample (59.6%) indicated that they had a current regular partner, while 
40.4% reported that they did not. 
Duration of Current Relationships 
These relationships ranged from two months to thirty one years. 
Sexual Orientation 
All the women were heterosexual, while all the men except two (95.1%) were gay. Two 
respondents did not identify their sexual orientation. 
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Domestic Circumstances / Living Arrangements 
Twenty four people (46.2%) lived alone, and 23, (44.2%) shared with their partner. One 
person, (1.9%) lived with a friend, one with their parents, one with their children, one in 
prison, and one in a community specifically for HIV positive people. 
Substance Use 
A quarter of the sample, (13 participants) reported no alcohol consumption, whilst the 
maximum number of units drunk per week was 30. The mean number of units was 7.08 
per week, (SD 8.72). 
Twenty one people, (40.4 %) indicated that they used some recreational drugs 
(i.e. cannabis, ecstasy, cocaine, speed, amyl nitrate, or valium). An equal proportion 
reported that they never used street drugs, and 10 people, (19.2 %) declined to answer 
the question. Cannabis was the most popular recreational drug, with 11 people, (21.2%) 
reporting at least occasional usage. 
Mood 
Anxiety scores for this population ranged from 0-19 with a mean score of 6.96 (SD 
4.86). Eight people (15%) obtained a score between 8 and 10 indicating possible 
psychiatric disorder. Twelve, (23%) scored over 10 indicating probable psychiatric 
disorder. The mean depression score was lower, (4.90, SD 4.32) although the range was 
the same, (0-19). The scores for six people (12%) fell into the possible psychiatric 
disorder range, and six (12%) into the probable psychiatric disorder category. 
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Coping 
From table 1 it can be seen that the sample utilised the full range of coping strategies 
with acceptance being the most widely used, followed by planning, emotional 
disengagement, positive reframing, humour and self-distraction. 
Table 1. Coping Strategies 
Range Mean SD. 
Self-distraction 1-8 4.40 1.76 
Active Coping 2-8 5.25 1.63 
Denial 1-8 2.81 1.52 
Alcohol and Drug 2-8 3.10 1.77 
Use 
Emotional 2-8 4.88 1.94 
Disengagement 
Behavioural 1-8 2.69 1.50 
Disengagement 
Venting 2-8 3.69 1.58 
Positive 2-8 4.83 2.13 
Reframing 
Planning 1-8 5.29 1.82 
Humour 1-8 4.56 2.23 
Acceptance 2-8 7.04 1.56 
Religion 2-8 3.52 2.23 
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Perceived Self-efficacy 
GSES 
The mean Generalised Self-Efficacy Score was 31.06 (range 14-57, SO, 7.04). This is 
higher than the mean score of29.28 (SO 4.6) obtained by Schwarzer (1993) from his 
German sample, but is not significantly different. The standard deviation in this sample 
is clearly greater. 
Medication-specific Self-efficacy 
Self-efficacy for adherence to specific medications. 
The mean score for the Composite measure of Self-efficacy for adherence to specific 
medications was 4.3925, (range 1-5, SO. 8.382). 
Self-efficacy for Medication-specific Problem Solving 
The mean score for the Composite measure of Self-efficacy for Medication-specific 
Problem Solving was 4.2343, (range 1-5, SO. 9.884). 
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Table 2. Summary statistics and reliabilities for the adapted Health Belief scales of 
theADQ. 
Table 2 illustrates that adequate alpha reliabilities were obtained for all the sub-scales of 
the ADQ with the exception of Subjective norms. 
Scale No. of items Range Mean SD Alpha 
Transformed Transformed Transformed Reliability 
0-100 0-100 0-100 
Interpersonal 9 50-100 78.6423 13.1659 .6857 
Aspects of 
Care 
Perceived 24 26.04-93.75 72.57 13.5160 .8693 
Utility 
Perceived 14 11.54-78.57 47.9798 13.0068 .7474 
Susceptibility 
Perceived 11 34.09-90.91 57.9545 13.2189 .5464 
Severity 
Intentions 7 7.14-100 84.5238 20.0593 .8974 
Supports and 12 22.92-100 67.0451 15.7553 .7719 
Barriers 
Perceived 18 5.56-100 79.8458 14.7147 .8980 
Self-Efficacy 
Subjective 5 43.33-100 62.4797 13.2849 .21 
Norm 
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Table 3. Inter-correlations between adapted ADQ subscales 
The inter-correlations between the ADQ subscales presented in Table 3 illustrate that 
the constructs measured by these subscales are not mutually exclusive. 
Interperson Perceived Perceived Perceived Intentions Perceived Perceived Subjective 
al Aspects Utility Susceptibil Severity Supports Sclf- Nonn 
of care ity and clficacy 
Barriers 
Interperson 1 .350* -.010 .111 .090 .346* .065 .259 
al Aspects 
of care 
Perceived 
.350* 1 -.083 . 065 .590 .... .685** .788 .... .504** 
Utility 
Perceived 
-.010 -.083 1 .273 .039 .041 -.033 -.120 
Susceptibil 
ity 
Perceived 
.111 .065 .273 1 .186 .042 .097 -.055 
Severity 
Intentions 
.090 .590** .039 .186 1 .642** .695** .208 
Perceived 
.346* .685** .041 .042 .642** 1 .715** .228 
Supports + 
Barriers 
Perceived 
.065 .788** -.033 .087 .695 .... .715** 1 .311 * 
Self-
efficacy 
Subjective 
.259 .504** -.120 -.055 .208 .228 .311 * 1 
Norm 
Significance levels *p<.05 **p<.01 
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IIIness Specific Information 
Participants' health status covered a wide spectrum. C04 counts ranged from a 
minimum of21 to a maximum of 850, with a mean of328.38 (SO 161.51). Seventeen 
people (32.7%) had undetectable viral loads, and four (7.6%) were in the 10-15,00 
range. The maximum viral load was 300,000. The length of time since their HIV 
diagnosis ranged from six months to 16.5 years with a mean of7.2 years, (SO 4.3806). 
Twenty-nine respondents, (56.9%) did not have an AIDS diagnosis while 22, (42.3%) 
did. One person did not answer this question. 
Medications Taken and Prevalence of Reported Side Effects 
The sample were taking different combinations of a total of 16 medications, see Table 4. 
There was a total of 41 different drug combinations. Excluding drugs for PCP 
prophylaxis, there were 35 antiretroviral drug combinations, which makes it impossible 
to analyse the adherence data by drug combination. 
Twenty-seven people (52%) reported experiencing side effects associated with 
11 drugs. The most frequently reported side effect was diarrhoea. The drugs associated 
with the greatest number of side effects were d4T, Indinavir, and Nevirapine. Over half 
of those taking Indinavir, and half of those taking Nelfinavir reported side effects. Over 
a third of those taking AZT described side effects as did just under a third of those on 
d4T. 
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Table 4. Medications Taken and Prevalence of Reported Side Effects 
Medication Frequency Percent No of People Side Effects Reported 
Reporting 
Side-effects 
AZT II 21.2% 4 Diarrhoea, nausea, and fatigue 
ddi 19 36.5% 5 Peripheral neuropathy, diarrhoea, nausea, 
and headache 
ddc 2 3.8% 0 
d4T 34 65.4% II Peripheral neuropathy (7) diarrhoea, 
nausea, insomnia, headache, and tardive 
dyskinesia. 
3TC 28 53.8% 4 Peripheral neuropathy (2), diarrhoea, and 
insomnia 
Nelfinavir 6 11.5% 3 Diarrhoea and lipodystrophy 
Ritonavir 3 5.8% 1 Diarrhoea and lipodystrophy 
Saquinavir 7 13.5% 2 Peripheral neuropathy (I ), and diarrhoea 
Indinavir 14 26.9% 9 Diarrhoea, post dosage discomfort, 
Iipodystrophy,(4), dermatological 
problems, nausea, insomnia, headache, 
fatigue, flatulence, and tardive dyskinesia. 
Nevirapine 21 40.4% 4 Peripheral neuropathy, diarrhoea, 
dizziness, dermatological problems, 
nausea, headache 
Delavirdine 0 0% 0 
dmp 4 7.7% 0 
Abacavir 5 9.6% 0 
Combivir 3 5.8% 0 
Septrim 14 26.9% 1 diarrhoea 
Dapsone 1 1.9% 1 diarrhoea 
Aerosolised 4 7.7% 0 
Pentamidine 
Adherence 
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This section is divided into Self-Perceived Adherence, Global Medication Adherence, 
(two measures), Medication-specific Adherence, (four measures) and three Composite 
Adherence Measures. This yields a total of 10 adherence measures. The Global 
measures refer to participants'responses to general questions about their adherence. The 
composite measures are calculated by summing medication-specific adherence measures 
for each drug. 
Person Specific Adherence 
Medication-specific Adherence 
1) Self-Perceived Adherence, 
2) Global adherence to dose times, 
3) Global adherence to special instructions, 
4) Composite dose omissions 
5) Composite dose delays 
6) Doses missed 
7) Dose delays 
8) Adherence to special instructions 
9) Frequency of disruption to drug routine 
10) Composite frequencies of disruptions to 
drug routine for entire sample 
This is followed by a section presenting more data on disruptions to drug regimes 
including 1) attributions for the last lapse, 
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2) triggers for the realisation that a disruption to the routine had occured 
3) individual beliefs about medication efficacy given the way they take their 
medications. 
Person Specific Adherence 
1. Self-Perceived Adherence 
42.3% of the sample considered themselves excellent at taking the drugs as prescribed. 
Half described themselves as good, 3.8% as reasonable and 1.9% as poor. One person 
declined to answer the question. 
Global Medication Adherence 
2) Global adherence to dose times, 
A quarter of the sample (25%) said they never changed their dosage times. 34.6% 
indicated that they did so occasionally, 25% sometimes, 9.6% usually, and 3.8% always. 
One person did not complete this question. Only one person, (1.9%) reported that they 
sometimes altered the drug dosage. Two people did not answer this question. 
3) Global adherence to special instructions, 
Almost half the sample, (48.1 %) said they never took their drugs without adhering to 
the prescribed regimen. A quarter indicated that they occasionally did, and 19.6% did 
so sometimes. 5.8% reported that this was a usual occurrence and 3.8% that it always 
happened. Three people did not respond to this question. 
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When asked whether they ever took drug holidays, 76.9% said they never did so 
and 21.2% replied that they occasionally did. 
4. Composite dose omissions 
No respondent reported missing a dose on the previous day. The total number of days 
on which doses were missed by this sample during the previous week was 48. Thirty 
seven people, (71.2% of the sample) indicated that they had not missed a dose on any 
day during the previous week. Fourteen people, (26.9%) had missed doses on one or 
more days. The number of days on which doses were missed by an individual during 
the previous week ranged from 0-7, with a mean of .9412, (SO 1.8912). 
5. Composite dose delays 
No respondent indicated that they had taken a dose late on the previous day. A total of 
111 doses were taken late by this sample during the previous week. Thirty people 
(57.7% of the sample) reported that they had not taken a dose late during the previous 
week. Nineteen people, (36.5%) indicated having taken one or more doses late. The 
number of doses taken late by an individual during the previous week ranged from 0-25, 
with a mean of 2.2653, (SD 4.9065). 
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Medication-specific Adherence 
6. Dose omissions and 7. Dose delays 
Table 5 presents data for dose omissions and dose delays by type of medication taken. 
Although the numbers taking each medication were insufficient to permit statistical 
analysis, the percentages on each medication reporting dose omissions or dose delays 
demonstrate wide variation. It is interesting that for some medications, no individuals 
reported missing or omitting doses. At the other end of the spectrum, 42.9% of those 
taking Indinavir reported dose delays. 
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Table 5. Dose Omissions and Dose Delays 
Dose Omissions Dose delays 
No of %of No of Mean SD No of %of Noof Mean SD 
people people days no of people people days no of 
om itt- onMx days delay- onMx days 
ing om itt- per ing delay- per 
doses ing total doses ing total 
byMx doses onMx byMx doses on Mx 
Medication 
AZT 0 0 0 0 2 18% 4 0.57 (1.13) 
ddi 4 21.1% 8 0.4706 (0.9432) 4 21.1% 19 1.375 (2.918) 
ddc 0 0 0 0 0 0% 0 0 
d4T 4 11.8% 5 0.1667 (0.4611) 7 20.6% 29 1.0357 (2.3802) 
3TC 5 17.9% 7 0.3182 (0.6463) 4 14.3% 10 0.5556 ( 1.2935) 
Nelfmavir I 16.7% I 0.25 (0.5) I 16.7% 2 0.5 (1.0) 
Ritonavir 0 0% 0 0 I 33.3% I 0.3333 (0.5774) 
Saquinavir 2 28.6% 2 0.3333 (0.5164) I 14.3% I 0.1429 (0.378) 
Indinavir 2 14.3% 4 0.3077 (0.7511) 6 42.9% 12 0.8571 (1.4064) 
Nevirapine 4 19.1% 12 0.6 (1.6351) 6 28.6% 18 1.1875 (2.0073) 
dmp I 25% 2 0.6667 (1.1547) 1 25% 2 0.6667 (1.1547) 
Combivir 0 0 0 0 1 33.3% 3 0.667 (l.1547) 
Abacavir 0 0 0 I 20% 3 1.0 (1.7321) 
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8) Adherence to special instructions 
Table 6 presents data on adherence to the special instructions for taking each drug. It 
should be noted that some drugs (such as those for PCP prophylaxis) do not have special 
requirements for their consumption, so the data on PCP prophylaxis has not been 
presented. Drugs with asterisks have special requirements, drugs with two asterisks, 
(protease inhibitors) require especially strict adherence to dietary restrictions and dose 
times. 
Table 6. Adherence to Special Instructions 
Always Usually Adhere to Occasionally Never 
adhere to adhere to special adhere to adhere to 
special special instructions special special 
instructions instructions 50% of time instructions instructions 
Medication n % n % n % n % n % 
AZT 1 9% 
ddi* 6 32% 5 26% 1 5% 1 5% 1 5% 
ddc 1 50% 
d4T* 5 15% 4 12% 1 3% 2 6% 
3TC'" 4 14% 4 14% 1 4% 
N elfinavir'" ... 1 17% 2 33% 
Ritonavir** 2 67% 1 33% 
Saquinavir* * 1 14% 2 29% 2 29% 
Indinavir'" ... 4 29% 5 36% 3 21% 
Nevirapine** 5 24% 1 5% 1 5% 
dmp 1 25% 
-Abacavir 
Combivir 
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7. Frequency of disruption to drug taking regime 
Table 7. Frequency of Disruption to Drug Regime 
Daily Almost 3-4 times 1-2 times 2-3 times Oneea Less 
daily weekly weekly monthly month than 
once a 
month 
% dose 50% 38% 29% 14% 5% 2% 
disruptions if 
twice daily 
regimen 
% dose 33% 24% 19% 10% 4% 1% 
disruptions if 3 x 
daily regimen 
approx. % range 50-67% 62-76% 71-81% 86-90% 95-96% 98-99% 100% 
of adherence 
Medication 
AZT 4 I 2 
ddi I 3 5 2 4 
ddc I 
d4T I I I I 5 15 
3TC 2 I I 3 3 10 
Nelfmavir I 2 I 
Ritonavir I 
Saquinavir 2 2 2 
Indinavir 2 1 1 6 
Nevirapine 1 1 1 4 7 
dmp 1 
~ 
Abacavir 2 
Combivir 1 2 
Septrim 4 
Dapsone 1 
Aerosolised I 
pentamidine 
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10. Composite frequencies of disruptions to drug routine for entire sample 
(calculated by summing responses for each drug) 
Table 8 illustrates that almost half the sample indicated that disruptions to their routine 
were rare, occurring less than once a month. 16% of the sample reported disruptions 
OCCurring at least once a week. 
Table 8. Composite Frequencies of Disruptions to Drug Routine 
Frequency Count % of Responses 
Every day 5 4.2 
Nearly every day 3 2.5 
3-4 times weekly 2 1.7 
1-2 times weekly 9 7.6 
2-3 times monthly 18 15.3 
Once monthly 23 19.5 
Less than once monthly 58 49.2 
Self reported explanation for last disruption to regime 
Table 9 illustrates the reasons reported for the last disruption to their regime. Just over a 
fifth of disruptions were attributed to being out of the house or away from their 
medications. Other major factors included falling asleep, and changes to their eating 
routine. 
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Table 9. Self Reported Explanation for Last Disruption to Regime 
Explanation Frequency % of responses 
Don't know 1 .9 
Excess alcohol or recreational 4 3.7 
drugs 
In hurry 4 3.7 
Did not want to take medication 5 4.7 
in front of others 
Ran out of medications 5 4.7 
Depressed 6 5.6 
Side effects 7 6.5 
Distracted 10 9.3 
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Factors leading to realisation that routine had been disrupted 
The most salient feature of the data presented in Table 10 is that three quarters of those 
providing data about factors involved in the realisation that doses had been missed, had 
realised spontaneously without prompts from people, alarms, or the cues provided by 
external events. 
Table 10. Factors Leading to Realisation that Routine had been Disrupted. 
Factor Frequency % of Responses 
Reminded by another 4 4.1 
person 
Reminded by timer or 6 6.1 
beeper 
Had leftover pills in 7 7.1 
plannerlbottle 
Reminded by other 8 8.2 
scheduled events 
Spontaneously 73 74.5 
remembered 
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Perceived Benefit 
Table 11 presents the data on perceived benefit of drugs. Half the sample believed they 
derived all possible benefit from their drugs. A quarter indicated that taking their drug 
taking behaviour into account, they think they get most of the benefit from their drug. 
One fifth consider the benefit obtained enough to make it worth taking, and only 1.8% 
reported believing the benefits obtained were less than that. 
Table 11. Perceived Benefit 
Degree of benefit Count 0/0 of responses 
Not much benefit 2 1.2 
Some benefit 1 .6 
Enough to make it worth 31 19.1 
taking 
Most of the benefit 38 23.5 
All possible benefit 89 54.9 
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3.3 Investigation of the Hypotheses 
HI. A positive relationship is predicted between perceived self-efficacy and 
adherence to combination drug therapies in HIV. 
Correlations 
Spearman's rho correlation coefficients were calculated for the three perceived self-
efficacy measures and the four adherence measures, see Table 12. 
~ 
No significant correlations were observed between GSES scores and the global 
measures of adherence to dose times, or adherence to special instructions. There was a 
modest negative correlation with the composite measure of dose omissions, (-.398, 
p<.O.O 1) but no significant correlation with the composite measure of dose delays. 
Self-efficacy for adherence to specific medications 
No significant correlations were observed between scores for self-efficacy for adherence 
to specific medications and the global measures of adherence to dose times, or 
adherence to special instructions. However, it was negatively correlated with both the 
composite measure of dose delays, (-.315, p<.05) and the composite measure of dose 
omissions, (-.548, p<.OI). 
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Self-efficacy for Medication-specific Problem Solving 
A similar but weaker pattern was observed for self-efficacy for medication-specific 
problem solving and adherence. There were no significant correlations with the global 
measures of adherence to dose times, adherence to special instructions, or the composite 
measure of dose delays. A significant negative correlation was obtained with the 
composite measure of dose omissions, (-.367, p<.O 1). 
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Table 12. Table of Correlations between Age, Depression score, Alcohol 
Consumption, General and Medication-specific Self-Efficacy and the Four 
Adherence Measures. 
Global Global Composite Composite 
adherence to adherence to dose omissions dose delays 
dose times special 
instructions 
Age 
-.083 .031 -.349** -.121 
HADS 
-.066 .224 .341 ** .059 
depression 
Score 
Units of 
.095 -.113 -.023 -.050 
alcohol 
consumed per 
week 
Generalised 
-.081 .077 -.398** -.123 
Self-efficacy 
Score 
Self-efficacy 
-.144 -.143 -.548** -.315* 
for adherence 
to specific 
medications 
Self-efficacy 
.066 .046 -.367** -.149 
for 
Medication-
specific 
Problem 
Solving 
Significance levels *p<.05 **p<.OI 
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H2. An inverse relationship is predicted between self-efficacy and depression. 
A Pearson's correlation coefficient was calculated using the HADS depression score 
and Generalised Self-efficacy Score. The correlation coefficient was calculated as r=-
.409 (p<.01). This suggests that depression and Generalised Self-efficacy are related, 
although distinct phenomena. However, there is some doubt as to whether it is 
appropriate to use the HAOS as a linear measure, and it has been suggested that it is best 
used as a categorical measure. Therefore, the recommended cut-offs were used to group 
the HADS scores into nonclinical, possible, and probable psychiatric disorder 
populations. A one-way Anova was performed (including Sheffe and LSO post-hoc 
analyses). This established that there was a significant difference between groups (F= 
6.198, p.004). Post-hoc tests identified that the differences in GSES scores lay between 
the non-clinical and the possible psychiatric disorder group, (p>.01). However, there 
were no significant differences between those with probable psychiatric disorder and the 
other two groups. 
Examination of the means for the three groups suggests that the explanation for 
this may lie in the spread ofGSES scores of those with probable psychiatric disorder. 
The mean GSES score for the non clinical group was 32.71, (SO 6.16), for the possible 
Psychiatric disorder group, 23.33, (SD 5.85), and the probable psychiatric disorder, 
27.50, (SO 9,09). 
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83. Irrespective of depression level, it is predicted that perceived self-efficacy 
. 
will account for a significantly greater proportion of the variance in 
adherence to antiretroviral medications than other variables known to be 
associated with adherence such as age, substance use, depression, AIDS 
diagnosis, and side effects. 
After computing the correlations between age, substance use, depression, GSES, the two 
medication-specific self-efficacy measures and the dependent variables, the four person-
specific adherence measures, (global adherence to dose times, global adherence to 
special instructions, composite dose omissions, and composite dose delays) the third 
hypothesis was tested by calculating four sets of regression analyses using the four 
adherence measures to assess the relative predictive power of those variables known to 
be related to adherence to antiretrovirals. 
Normal distribution could not reasonably be assumed for the four adherence 
Variables so Spearman's rank correlations coefficients were calculated, (see Table 12). 
Since an AIDS diagnosis and the experience of side-effects are categorical measures, 
Mann Whitney U tests were conducted. 
Age 
Age was not significantly correlated with the measures of global adherence to dose 
times, global adherence to the special instructions, or the composite dose delays. There 
was, however, a weak negative correlation, (-.349, p<O.OI) with the measure of 
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composite doses missed. This finding is in keeping with the results from other studies 
which find adherence increases with age. 
Substance Use 
Alcohol 
No significant correlations were observed with any of the four adherence variables. 
Recreational Drug Use 
Since whether or not people engage in recreational drug use is a categorical measure, 
Mann Whitney Utests were performed with each ofthe four adherence measures. No 
significant results were obtained. 
Depression 
The HADS depression scores were not correlated with the measures of global adherence 
to dose times, global adherence to the special instructions or the composite measure of 
dose delays. On the other hand there was a statistically significant correlation with 
composite doses omissions, (.341, p.<O.OI). When Mann Whitney Utests were 
conducted using the HADS as a categorical measure, no significant associations were 
found with any of the four adherence measures. 
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AIDS diagnosis 
A Mann-Whitney Utest was conducted for AIDS diagnosis with each of the four 
adherence variables. No statistically significant results were obtained with the global 
measures of adherence to dose times, or adherence to special instructions, or the 
composite measure of dose omissions. However, a statistically significant inverse 
association was observed with composite dose delays (z =-2.619, p>O.05). This is 
unexpected given that previous research has found that people with prior experience of 
oPportunistic infections, (one of the defining criteria for an AIDS diagnosis) display 
greater adherence. 
Side-Effects 
Whether or not participants experienced side-effects is also a categorical measure, so 
Mann-Whitney U tests were conducted. No statistically significant associations were 
observed with any of the four adherence variables. 
Perceived Self-efficacy 
The correlations for GSES, and medication-specific self-efficacy have already been 
presented in relation to the first hypothesis, see Table 12. 
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Regressions 
Multiple Regressions 
All the above measures were put into the regression analyses. Each regression was 
calculated twice, initially using the total HADS depression scores, and subsequently 
using it as a categorical measure in a stepwise regression, although this did not appear to 
affect whether predictors of adherence emerged from the analyses. 
1) Global adherence to dose times, 
Multiple Regression 
When the global measure of adherence to dose times was used as the dependent 
variable, the proportion of the variance accounted for was 18.6%, (F=.661, NS). This 
was insufficient for any individual variable to emerge as a statistically significant 
predictor. 
StepWise Regression 
Conducting a stepwise regression with depression classified as absent or possibly 
present, only 4.5% of the variance was accounted for, (F=.328, NS) which was 
inSufficient for any single variable to emerge as a significant predictor. 
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2) Global adherence to special instructions, 
Multiple Regression 
Substituting global adherence to special instructions as the dependent variable increased 
the proportion of the variance accounted for to 24.8%, (F=.877, NS). However, no 
significant predictors were identified by the analysis. 
Stepwise Regression 
Using the categorical measure of depression in a stepwise regression, 8.5% of the 
variance was accounted for, (F=.610, NS). 
3) Composite dose omissions 
Multiple Regression 
Using the composite measure of dose omissions as the dependent variable, 39.7% of the 
variance was accounted for, (F=1.830, NS). However, only the use of recreational drugs 
emerged as a significant predictor, see Table 13. Only the significant predictor is 
included in the table. 
Table 13. Multiple regression analysis for composite dose omissions 
Dependent variable Independent Beta t R d.f. 
variables Square (total) 
-Composite dose Use of recreational .445 2.386* .397 25 
omissions drugs 
Significance level *p<.05 
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Stepwise Regression 
To investigate whether other variables would emerge as significant once recreational 
drug use was controlled for, a stepwise regression was conducted entering recreational 
drug use as the first variable, see Table 14. Recreational drug use accounted for 15.6% 
of the variance, (F=6.120, p> .02) when this was controlled for, self-efficacy for 
adherence to specific medications emerged as a significant predictor, adding a further 
12.7% of the variance, (F=6.324, p> .005). 
Table 14. Stepwise regression analysis for composite dose omissions 
Dependent variable Independent Beta t R 
variables entered Square 
stepwise 
Composite dose Use of recreational .396 2.474 .156* 
omissions drugs 
Self-efficacy for -.357 -2.380 .283*** 
adherence to 
specifi~ medi~ations 
Significance levels *p<.02 **p<.Ol ***p<.005 
Recalculating the stepwise regression analysis with the categorical measure of 
depression as the first variable entered, 18% of the variance was accounted for, 
(F==I.490, NS) without any single variable emerging as a significant predictor. 
d.f. 
(total) 
32 
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4) Composite dose delays 
Multiple Regression 
Results 
Using this measure as the dependent variable the proportion of the variance accounted 
for was 42.9%, (F=2.001, p>.09). Both Medication-specific self-efficacy measures 
emerged as significant predictors. Only these significant predictors are included in table 
15. 
Table 15. Multiple regression analysis for composite dose delays 
Dependent variable Independent Beta t R d.f. 
variables Square 
Composite dose Self-efficacy for -.751 -2.412* .429 24 
delays adherence to specific 
medications 
Self-efficacy for .531 -2.191 * 
Medication-specific 
Problem Solving 
Significance levels *p<.05 **p<.Ol 
StepWise Regression 
Both self-efficacy for adherence to specific medications, and self-efficacy for 
medication-specific problem solving were entered as the first two variables in a stepwise 
regression analysis, but no other significant predictors emerged. 
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Performing a stepwise regression with depression classified as a categorical measure, 
14.5% of the variance was accounted for, (F=1.084, NS) with no significant predictors 
identified by the analysis. 
H4. A positive relationship is predicted between perceived self-efficacy and 
adaptive coping strategies, such as acceptance, active coping, positive 
reframing, and planning. 
Adaptive coping scores were obtained by summing the scores from the acceptance, 
active coping, positive reframing, and planning variables. A Pearson correlation was 
conducted using the GSES and adaptive coping variables. A modest correlation of 
0.321 was obtained (p<.05). Further analysis with the individual variables, acceptance, 
active coping, positive reframing and planning revealed that only one variable, positive 
reframing, was significantly correlated with GSES (0.371, p.<.Ol). Acceptance was 
not normally distributed so a Spearman's rho correlation coefficient was calculated for 
this variable. No significant correlations were obtained with acceptance, active coping, 
or planning. 
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US. An inverse relationship is predicted between perceived self-efficacy and 
maladaptive coping strategies, such as denial, behavioural disengagement, 
self-distraction, alcohol and substance use. 
Maladaptive coping scores were obtained by summing the scores from the denial, 
behavioural disengagement, and self-distraction variables. They were then recalculated 
to include alcohol and substance abuse. A similar analysis was conducted with the 
GSES and total maladaptive coping score, and a correlation of -.306 was obtained, 
(p<.OS). Individual maladaptive coping strategies were also correlated sepatrately with 
GSES. This showed that behavioural disengagement and GSES were correlated -.333, 
(p<.OS), but neither denial nor self-distraction were correlated with GSES. A weak but 
statistically significant correlation (.261, p.<.05) was obtained when alcohol and 
substance use was correlated with GSES. 
H6. Self-efficacy will account for a greater proportion of the variance than 
other Health Belief components of the Health Action Process Approach 
(interpersonal aspects of care, perceived susceptibility, perceived severity, 
intentions, supports and barriers, and subjective norms). 
The means for interpersonal aspects of care, perceived utility, perceived severity, 
perceived susceptibility, subjective norms, intentions, supports and barriers, and 
perceived self-efficacy were linearly transformed to a 0-100 scale and entered into 
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multiple and stepwise regressions using each of the four adherence measures as the 
dependent variable. 
The number of items, score range, mean and standard deviations (transformed 
linearly to a 0-100 scale), and Cronbach's alpha reliability for each of the final subscale 
measures are presented in Table 2. 
1) Global adherence to dose times, 
When this measure was used as the dependent variable, 24% of the variance was 
accounted for (F= 1.530, Sig.179). No component of the model emerged from the 
multiple regression as a statistically significant predictor of this measure of adherence, 
or indeed from a stepwise regression. 
2) Global adherence to special instructions, 
When global adherence to special instructions was substituted as the dependent variable 
in the mUltiple regression, 15.2% of the variance was accounted for, (F=.807 Sig .601) 
and no significant predictors were identified by this analysis or by a stepwise regression. 
3) Composite dose omissions 
Using composite dose omissions as the dependent variable, the components of the 
model accounted for 17.3% of the variance (F=.992 Sig .458) without any individual 
component emerging as a significant predictor. A stepwise regression was also 
performed but did not identify any significant predictors. 
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4) Composite dose delays 
Using composite dose delays as the dependent variable in a multiple regression, the 
components of the model accounted for only 9.1 % of the variance, (F=.464 Sig .874). 
No single statistically significant predictor emerged from the mUltiple regression, or 
indeed, from a stepwise regression. 
Additional Analyses 
Further Spearmans rank correlations between the coping variables and the four measures 
of adherence were calculated, see Table 16. From this table it can be seen that denial 
coping was positively correlated with the composite measure of doses missed, (.396, 
P·>OI). a weak correlation was also obtained between substance use and the global 
measure of adherence to dose times, (.296, p>.05) and, more robustly, with the measure 
of dose omissions, (.520, p>.OI). Use of emotional support was negatively correlated 
with the composite measure of dose omissions, (.363 p>.05). 
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Table 16. Correlations between coping strategies and adherence measures 
Global Global Composite Composite 
adherence to adherence to dose dose delays 
dose times special omissions 
instructions 
Self-Distraction 
.092 .067 .013 -.062 
Active Coping 
-.214 -.024 -.272 -.143 
Denial 
.018 .096 .396** .073 
Alcohol + Drug 
.296* .035 .520** .227 
Use 
Use of Emotional 
.072 .272 -.363* -.262 
Support 
Behavioural 
.030 -.251 .102 -.090 
Disengagement 
Venting 
.128 -.266 .121 .045 
Positive Reframing 
-.001 -.050 -.033 .081 
Planning 
-.232 -.172 .064 .051 
Humour 
.098 -.035 -.015 -.043 
Acceptance 
.110 -.224 -.068 .176 
f-
Religion 
-.078 -.005 .151 .172 
~ 
Adaptive Coping 
-.092 -.131 -.091 .052 
Maladaptive 
.083 .044 .209 -.092 
Coping 
-
Maladaptive 
.141 .090 .343* .031 
COping, (including 
SUbstance use) 
'--
Significance levels *p<.05 **p<.Ol 
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Four stepwise regressions were also conducted using the four measures of adherence as 
dependent variables. 
1) Global adherence to dose times, 
When a stepwise regression was conducted using global adherence to dose times, the 
Use of alcohol and drugs as a coping strategy accounted for 17.3% of the variance and 
was statistically significant as a predictor of this measure of adherence, p>.05, (F=8.347, 
Sig .. 006). 
2) Global adherence to special instructions, 
The stepwise regression did not identify any coping strategy as a significant predictor of 
this measure. 
3) Composite dose omissions 
When a stepwise regression was conducted using the measure of composite dose 
omissions, the use of alcohol and drugs as a coping strategy accounted for 21.1 % of the 
variance and was statistically significant as a predictor of this measure of adherence, 
P>.05, (F=10.691, Sig .. 002). 
4) Composite dose delays 
The stepwise regression failed to identify any coping strategy as a significant predictor 
of this measure. 
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Summary of findings 
HI. A positive relationship is predicted between perceived self-efficacy and 
adherence to combination drug therapies in HIV. 
• For two out the four adherence measures (the global measures of adherence) there 
were no correlations with any of the self-efficacy measures. 
• However, all three self-efficacy measures were negatively correlated with the 
measure of dose omissions. 
• The measure of self-efficacy for adherence to specific medications was also 
negatively correlated with the composite measure of doses delayed. 
H2. An inverse relationship is predicted between self-efficacy and depression. 
• The Generalised Self-efficacy Scores and the HADS depression scores were 
negatively correlated. However, there is no data on the use of the HADS as a linear 
one. Using the HADS as a categorical measure, and conducting a one way Anova 
established significant differences between those in the non-clinical range, and those 
with possible psychiatric disorder. No significant differences in GSES scores 
between those with probable psychiatric disorder and the other two groups were 
observed. 
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H3. Irrespective of depression level, it is predicted that perceived self-efficacy 
will account for a significantly greater proportion of the variance in 
adherence to antiretroviral medications than other variables known to be 
associated with adherence such as age, substance use, AIDS diagnosis, and 
side-effects. 
• Only three of the factors, (age, depression, and recreational drug use) identified from 
previous research as predictive of adherence were associated with the measures of 
adherence in this study. 
Doses Omissions 
• For two out of the four measures of adherence, (the global measures), no significant 
predictors emerged from regression equations. 
• Recreational drug use, but not depression, age, or the experience of side-effects, was 
the only significant predictor of composite dose omissions to emerge from a multiple 
regression analysis. 
• Once recreational drug use was controlled for, in a stepwise regression, self-efficacy 
for adherence to specific medications emerged as a significant predictor. 
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Dose Delays 
• When the number of doses delayed was taken as the dependent variable, the only 
predictors were the two medication-specific self-efficacy measures, self-efficacy for 
adherence to specific medications and self-efficacy for medication-specific problem 
solving. These two measures accounted for 42.9% of the variance. Conducting an 
additional stepwise regression to control for medication-specific self-efficacy, did not 
lead to any other variables emerging as significant predictors. 
84. A positive relationship is predicted between perceived self-efficacy and 
adaptive coping strategies, such as acceptance, active coping, positive 
reframing, and planning. 
• GSES was significantly associated with adaptive coping, although when the 
relationships with the individual components of adaptive coping were examined, 
significant correlations were only observed with positive reframing. 
85. An inverse relationship is predicted between perceived self-efficacy and 
maladaptive coping strategies, such as denial, behavioural disengagement, 
self-distraction, alcohol and substance use. 
• GSES was negatively correlated with maladaptive coping. Further investigation of 
the relationship between GSES and individual elements of maladaptive coping found 
88 
Results 
no significant association with denial or self-distraction, but a significant correlation 
with behavioral disengagement (and also with substance abuse). 
H6. Self-efficacy will account for a greater proportion of the variance than 
other Health Belief components of the Health Action Process Approach. 
Entering the Health Belief components of the Health Action Process Approach into 
multiple regressions with the four adherence measures as dependent variables accounted 
for up to a quarter of the variance, but no element of the model emerged as a significant 
predictor from mUltiple or stepwise regressions. 
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4. Discussion 
This section will provide a detailed analysis of this research and its contribution to the 
body of knowledge outlined in the introduction. It will be subdivided as follows: 
• interpretation of the results in relation to previous research into adherence in HIV. 
• interpretation of the results in relation to general adherence research, 
• interpretation of the results in relation to the hypotheses, 
• interpretation of the results in terms of the theories presented, 
• methodological considerations, 
• clinical and service implications, 
• suggestions for further research, 
• conclusions. 
4.1 Interpretation of the results in relation to previous research into adherence in 
HIV. 
-
High rates of adherence were reported across all adherence measures by this sample, 
although there was considerable variation between measures. Previous research has 
identified that people are normally accurate about non-adherence but tend to 
overestimate adherence. Research into adherence in other conditions suggests that the 
more specific the questions asked, the more accurate the information obtained. The 
findings from this study are consistent with this pattern. The levels of adherence 
reported when participants were asked global questions about their adherence were 
higher than those obtained by summing responses to questions about individual drugs, 
thereby forming composite measures. 
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In the current study, the greater the specificity of the adherence measure, the higher 
the rate of non-adherence reported. Since patients' reports of non-adherence are 
usually accurate, (Fletcher, 1989, cited in Myers & Midence, 1998), one can assume 
that these specific measures are more accurate than the global ones. Similarly, the 
strength of the association between the medication specific measures of self-efficacy 
and the composite measures of adherence lends further support to Bandura's 
contention about the specificity of self-efficacy judgements. 
Different patterns were obtained for the measure of dose omissions and dose 
delays which suggests that the processes involved might be subtly different, although 
clearly related. 
Overall, 42.3% of this sample considered themselves excellent, and half, good, 
at taking their drugs as prescribed. More detailed questions elicited information 
which suggests a discrepancy between the self perception and the reality of their 
medication taking behaviour. When asked specifically about dose timing, 25% 
reported that they sometimes took doses late, while 10% usually or always did so. 
This indicates that a third of this sample struggle with this aspect of adherence. When 
asked about dose delays for individual drugs, 36.5% had taken a dose late on one or 
more days during the previous week. 
Fewer people had missed doses altogether, although just over a quarter 
reported that they had missed a dose on at least one day during the previous week. 
Almost half the sample said that they never took their drugs without adhering 
to the special instructions. 29.9% said they sometimes, usually or always, neglected 
to follow the special instructions. 
91 
Discussion 
Consistent with the findings from previous research, this study found age, depression, 
self-efficacy and substance use were associated with adherence, although only 
substance use and self-efficacy emerged as significant predictors in regression 
analyses. 
No relationship between side-effects and adherence was observed. This may 
be because medical management of side-effects within this service keeps side-effects 
to a minimum. The presence or absence of side-effects may be too simplistic a 
measure, and it may be the type of side effect that is important. Certainly, anaemia, 
leukopenia and diarrhoea are known to affect adherence. Alternatively, it may be the 
level of side-effects experienced. People may be able to tolerate side-effects and their 
impact on their lives up to a certain threshold, after which adherence declines. 
This sample size was insufficient to test whether sex or race was related to 
adherence in this study. 
This sample had had quite some time to become accustomed to their HIV 
diagnoses and their treatments. Previous research suggests that most difficulties with 
adherence are experienced when commencing treatment, with people gradually 
incorporating their medications into their routines over the first few months. 
However, Gallant & Block's research, (1988) suggests that there may be a plateau 
effect with the number of drug holidays increasing after two years. It may be that 
accidental, passive non-adherence is greater at the start of treatment, while deliberate, 
active non-adherence is more prevalent later on, although only one person in this 
sample reported taking drug holidays. 
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Unlike previous research, (Singh et al. 1996) this study did not find a positive 
relationship between adaptive coping and adherence. 
4.2 Interpretation of the results in relation to general adherence research 
The finding that active coping was not associated with adherence is consistent with 
the results from the MOS study, (Sherbourne et al. 1992). Similarly the relationship 
between denial coping and adherence observed in this study has been identified in 
other studies, (Croog, Shapiro, & Levine, 1971, cited in Sherbourne, 1992). 
4.3 Interpretation of the results in relation to the hypotheses, 
HI. A positive relationship is predicted between perceived self-efficacy and 
adherence to combination drug therapies in HIV. 
Both the general and the two medication specific measures of self-efficacy were 
related to adherence measured by dose omissions. Self-efficacy for adherence to 
specific medications was also related to adherence measured in terms of doses 
delayed. These findings provide support for the thesis that perceived self-efficacy and 
adherence are related although the relationship appears to be stronger when 
considering dose omissions than dose delays. 
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H2. An inverse relationship is predicted between self-efficacy and depression. 
A strong negative correlation was observed between the general measure of self-
efficacy and depression. As there is no data on its use as a linear measure, further 
analysis was conducted as a categorical measure which established no significant 
differences in GSES scores between the clinical and non clinical groups. These 
findings suggest that while depression and a lack of perceived self-efficacy may be 
related, the relationship is not a simple one, and depression and self-efficacy are 
distinct phenomena. Depression is clearly more than just an absence of self-efficacy. 
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83. Irrespective of depression level, it is predicted that perceived self-efficacy 
will account for a significantly greater proportion of the variance in 
adherence to antiretroviral medications than other variables known to be 
associated with adherence such as age, substance use, depression, AIDS 
diagnosis, and side-effects. 
Contrary to the findings from other studies, depression did not emerge from 
regression equations as a predictor of any of the four measures of adherence, although 
it was correlationally related to the composite measure of dose omissions. 
Recreational drug use was the only predictor of dose omissions identified by multiple 
regression. However, controlling for drug use in a stepwise regression allowed self-
efficacy for adherence to specific medications to predict a further 12.7% of the 
variance. These findings demonstrate that for this sample, recreational drug use is the 
most crucial factor in predicting non-adherence in terms of missed doses. 
Nevertheless, once this is taken into account, perceived self efficacy for adherence to 
specific medications emerges as a significant predictor. The correlation between 
depression and adherence suggests that drug use and self-efficacy may be masking the 
contribution made by depression. 
The picture for dose delays was clearer in that both forms of medication 
specific self-efficacy, (but not drug use) were the only predictors to emerge from 
multiple or stepwise regression analyses. 
Taken together these findings provide some support for this hypothesis 
although the evidence is stronger for dose delays than for dose omissions, for which 
recreational drug use is the most important factor. 
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H4. A positive relationship is predicted between perceived self-efficacy and 
adaptive coping strategies, such as acceptance, active coping, positive 
reframing, and planning. 
It would appear that general self-efficacy as measured by the GSES, and adaptive 
coping are indeed associated, although the effect appears to be accounted for by the 
relationship between GSES and positive reframing. 
HS. An inverse relationship is predicted between perceived self-efficacy and 
maladaptive coping strategies, such as denial, behavioural 
disengagement, self-distraction, alcohol and substance use. 
GSES is inversely related to the use of maladaptive coping strategies, although this 
may be a function of the relationship between GSES and behavioural disengagement, 
since no significant relationship with denial or self-distraction were observed. 
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H6. Self-efficacy will account for a greater proportion of the variance than 
other Health Belief components of the Health Action Process Approach 
(interpersonal aspects of care, perceived susceptibility, perceived severity, 
intentions, supports and barriers, and subjective norms). 
The Health Belief components of the Health Action Process Approach did not account 
for more than a quarter of the variance, whichever measure of adherence was used. 
This was not sufficient for any single component to emerge as a predictor. Such 
findings do not provide support for this model. 
4.3 Interpretation of the results in terms of the theoretical background of the 
stUdy. 
Self-Efficacy 
Perceived Self-Efficacy and Adherence 
Self-efficacy may mediate adherence through its effect on dealing with setback. 
Forgetting a dose, (whether or not one remembers before one is due to take the next 
dose) may have some similarities to the experience of relapse / abstinence violation 
for drinkers or smokers, a process studied by Marlatt & Gordon, (Marlatt & Gordon, 
1980, cited in O'Leary, 1985). These authors suggest that people who relapse 
attribute their slip to personal shortcomings which decreases their perceived self-
efficacy for remaining abstinent. Self-efficacy may buffer the experience of setback, 
more generally. Certainly, research with smokers has identified that post intervention 
self-efficacy is the best predictor of smoking cessation 
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Perceived Self-Efficacy and Mood 
The findings from this study provide some correlational support for Bandura' s (1997) 
proposition that perceived self-efficacy is inversely related to depression, although 
significant differences were not confirmed by a one way Anova. 
The development of the new combination drug therapies offers HIV positive 
people a source of perceived control over the disease. It is possible, as Bandura, 
(1982) has argued, that a situation of perceived control is potentially distressing for 
those whose self-efficacy about their ability to use it is low. The option of 
combination therapy may then be a source of distress for those with low self-efficacy. 
Perceived Self-Efficacy and Coping 
Perceived self-efficacy and choice of coping strategy were related in this sample. 
High levels of perceived self-efficacy were associated with adaptive coping and low 
levels with maladaptive coping. However, it would appear from these results that 
perceived self-efficacy, or its lack, is more strongly associated with some strategies 
than with others. In particular, it was positively associated with positive reframing, 
and negatively correlated with behavioural disengagement. This is consistent with the 
prediction (Bandura, 1997, O'Leary, 1985) that lack of efficacy in relation to a 
Particular goal, leads to the abandonment of efforts to achieve it. 
It may be that self-efficacy is particularly important in situations of uncertainty. 
One of the few consistencies in the experience of people with HIV has been 
uncertainty about the disease, its prognosis and its treatment. Even now, the situation 
is constantly changing. The comparison between receiving an HIV diagnosis with 
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receiving a diagnosis of diabetes illustrates this difference. People with diabetes 
know roughly what they can expect and what influences the outcome. Much less is 
known about HIV and in these circumstances perceived self-efficacy may be the more 
important. 
It is people who are already socially disadvantaged and vulnerable, (through 
race, drug use, abuse histories, sexual orientation) who are at greatest risk ofHIV. 
For some, the experience of discrimination and adversity will have reduced their 
general sense of self-efficacy (although it is interesting that the mean GSES score 
reported by this sample was not significantly different from Schwarzer's German 
sample, 1992). 
Health Action Process Approach 
The findings of this study suggest that perceived-self efficacy for adherence to 
specific medications may be an important predictor of adherence, which would need 
to be incorporated in any model. However, these results do not provide support for 
the Health Action Process Approach, the model which gives greatest weight to the 
influence of self-efficacy. At its most successful, in predicting the global measure of 
adherence to dose times, components of the Health Action Process Approach 
accounted for 24% of the variance which is roughly comparable to the average 
ProPortion of the variance accounted for by components of the Health Belief Model, 
according to the meta-analysis conducted by Zimmerman & Vemberg, (1994, cited in 
Home & Weinman, 1998). 
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Coping 
The strongest correlation between coping strategy and adherence was the positive 
relationship between alcohol and drug use, and the composite measure of doses 
missed. This corroborates the earlier finding linking recreational drug use with non-
adherence. A positive relationship between denial and the composite measure of dose 
omissions was also obtained. This may reflect an aspect of avoidance coping which 
has been has been found to be related to adherence in other studies, (Sherbourne et al. 
1992). 
It is interesting that the use of emotional support is negatively correlated with 
dose omissions. 
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A number of methodological issues need to be taken into consideration when 
interpreting these results. 
Design 
Discussion 
Clearly, cross-sectional research cannot establish the direction of causality, only the 
existence of relationships between the dependent and independent variables, which 
may be attributable to the presence of a third unexamined variable. It is also possible 
that as Borkovec, (1978, cited in Eastman & Marzillier, 1984) Eastman & MarzilJier 
(I 984) have argued, that self-efficacy represents more or less accurate judgements of 
people's past adherence behaviour. Adherence is better conceived of as a process 
requiring longitudinal study 
Measures 
The questionnaire developed for this study was both long and repetitive, especially for 
those on many drugs. This was due to the attempt to achieve methodological rigour. 
Whilst every effort was made to keep the questionnaire concise, this may have 
deterred some from participation. Equally, participants may have become fatigued 
and spent less time considering the accuracy of their responses. 
This is a new and complex area of research, and as yet there is an absence of 
established methodology for measuring adherence, health beliefs, or self-efficacy in 
people with HIV. All the measures were self-report measures and there was no 
corroboration with objective measures. It is likely, therefore, that adherence has been 
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overestimated and possible that social desirability factors influenced responses to all 
measures. 
Treatment Adherence Measures 
Most crucially, no objective measures of adherence are available. 
Mood 
There does not appear to be a scale for measuring the extent of depression in people 
with physical conditions, let alone one standardised on an HIV positive popUlation. 
Coping 
Given the average length of time since diagnosis, the situational version of the COPE 
may have been inappropriate. Use of this measure also precluded investigation of the 
relationship between avoidant coping and adherence in this popUlation, a relationship 
which has been established in other chronic conditions, (Sherbourne et al. 1992). 
Research into coping in HIV positive populations has used a variety of coping 
measures: the Dealing with Illness Coping Measure (Fukunishi et al. 1996), the HIV 
Coping List, (Mulder et al. 1995), or the Ways of Coping Revised Checklist, 
(Folkman & Lazarus, 1980, 1985, Sharts-Hopko et al. 1996) which hinders 
comparison across studies. 
Coyne & Gottlieb (1996) identify various drawbacks to the use of standardised 
coping checklists. Amongst other issues they suggest that many habitual coping 
responses become automatic and may not therefore be recognised as coping strategies 
by respondents. 
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Generalised Self-Efficacy Scale 
All the nonnative data for this measure has been collected from Gennan samples and 
may not generalise to other populations. 
H/V specific Health Beliefs 
Reliability and validity have not been established for this questionnaire in its adapted 
fonn, nor has it been standardised on an HIV positive population. It could be argued 
that it is not a valid measure of the Health Action Process Approach, as it does not 
directly assess social support but confines itself to the measurement of subjective 
nonns. Social support may be a powerful determinant of adherence in HIV. It is 
worth noting, on this point, that the use of emotional support was positively correlated 
with adherence, (as measured by dose omissions). 
Sample 
The small sample size means conclusions must be drawn with caution. In addition the 
self-selecting nature of the sample brings dangers of bias. However, the most serious 
methodological weakness of the study concerns the recruitment of the sample. The 
deSign approved by the ethics committee entailed the initial approach to patients 
being made by the researcher. However, this approval was necessarily subject to the 
consent of the consultants with clinical responsibility for each patient. One consultant 
insisted that the initial approach be made by doctors. In order to ensure that none of 
her patients were inadvertently approached, and to ensure consistency, all approaches 
to patients on the St Bartholomew's site were made by doctors during clinic 
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appointments. This reduced the numbers available for recruitment by excluding the 
large numbers of patients waiting to see other health professionals. 
This clearly introduces a potential source of selection bias into the system. 
When these concerns were expressed to one of the registrars, he remarked, "There's a 
selection bias at work, we tend to send only the adherent, uncomplicated people your 
way . .. This suggests that there was indeed a selection bias in operation for at least one 
doctor, although physician estimates of adherence are generally unreliable, (Ley, 
1988). It suggests that those obviously struggling with adherence and open with their 
doctor were not asked to participate. This clearly casts doubt on the representative 
nature of the sample. It would seem reasonable to assume that those who agree to 
Participate in research are likely to be more adherent than those who decline. 
Including another source of bias into the process is likely to have resulted in a sample 
further skewed towards adherence. 
Additionally, those with severe physical or psychological illnesses were 
excluded from the study, and it is impossible to know how this affected the results. In 
other research, poor health is associated with greater adherence, although in this 
sample poorer health status, as indicated by the presence of an AIDS diagnosis was 
correlated with more dose omissions. 
It is therefore possible that the trends apparent in these results would be more 
pronounced in a more representative sample, although this could only be established 
by further research. 
It is also possible that despite assurances of confidentiality, participants were 
concerned that information would be relayed to their doctors. The fact that initial 
approaches were made by doctors may have served to blur the distinction between the 
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researcher and the clinicians. Concerns about confidentiality were certainly 
expressed. A number of African women declined to take part, once they realised 
participation involved signing a consent form, even though this would be kept 
separate from the questionnaire which was, itself, anonymous. 
4.6 Clinical and service implications 
One of the more important findings of this study is the higher rates of non-adherence 
obtained from drug specific self-report measures compared with global measures. 
This certainly suggests that reliance on responses to global questions may 
overestimate adherence. 
The most effective strategy might be to incorporate more detailed adherence 
monitoring into standard care, with patients routinely asked to complete brief 
adherence measures about dose omissions, dose delays, and adherence to special 
instructions while they wait for appointments. This would provide an opportunity for 
discussion of any problems with their doctor. Monitoring self-reported adherence in 
the way that CD4 counts and viral load are routinely monitored would allow patients 
to receive direct feedback on the relationship between the two (and reinforcement). 
Conversely, it might also prevent those who do not respond to medication being 
labelled as nonadherent. 
A process more sensitive to detecting adherence difficulties would also allow 
for other forms of intervention. This is surely classical clinical psychology territory. 
Psychologists already have expertise in working with people to change their habits, 
(admittedly, normally to relinquish rather than reinforce them, but it is part of the 
same process). Health psychologists have well established roles in working with 
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people with diabetes to increase their adherence to diet and exercise regimes. This 
knowledge base could be applied to working with adherence in HIV. In many areas 
this is already happening, although rarely in an explicit fashion which allows for 
monitoring of the intervention. 
Clearly, further research is needed to clarify the role of self-efficacy. Should it 
prove to be as significant as the results of this study suggest, it is easily monitored 
and, moreover, amenable to intervention, (Gattuso et al. 1992). 
Since self-efficacy expectations are formed partly on the basis of perceptions 
about past behaviour, it is important that people do not underestimate their previous 
adherence. It is therefore important that people begin combination therapy with 
realistic expectations and are prepared for the occasional lapse. Catastrophic 
interpretations of the meaning offorgetting a dose may dramatically reduce self-
efficacy and thus adversely effect adherence. 
Given the relationship between recreational drug use and dose omissions, and 
the proportion of this sample using drugs, it would seem wise to ask patients about 
their drug use before they start combination therapy, so patient and clinician can 
discuss strategies for minimising the risk of dose omissions. It may be that alarms 
would prove particularly useful at such times. Some regimes are more forgiving of 
lapses than others, so it might be prudent to select one of them for people whose 
recreational drug use places them at risk of impaired adherence. 
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4.7 Suggestions for further research 
Further studies are needed to confirm the causal relationship between perceived self-
efficacy and adherence using prospective longitudinal designs in which a range of 
adherence measures are used. Measures of both depression and self-efficacy are 
needed to ascertain which is the crucial variable. 
Ideally, in order to minimise sampling issues, standardised adherence 
monitOring needs to be incorporated into the routine care of HIV positive patients. 
This would permit the tracking of longitudinal fluctuations in adherence. 
Considering that group interventions for people with HIV are now well 
established, it ought to be possible to integrate components targeting self-efficacy 
acquisition into existing interventions, such as Coping Effectiveness Training. This 
would allow for the assessment of the effects of Coping Effectiveness Training 
incorporating self-efficacy acquisition on adherence, relative to standard Coping 
Effectiveness Training or routine care. 
Research could establish whether adherence to medication, and other forms of 
problem focused coping are associated with high levels of general and specific self-
efficacy. 
In addition to the health benefits for individual patients, this could increase our 
understanding of adherence in its widest sense, and might help those with conditions 
other than HIV. 
To facilitate this process, further work is needed developing measures 
standardised on patients with chronic illnesses, and preferably on HIV positive 
populations. This would allow for further testing and refinement of the models used 
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to predict adherence which have not proved especially powerful in this study, or 
others, so far. 
It may be that current models are too simplistic and that frameworks need to 
be developed integrating coping theory with existing models. The relationship 
between perceived self-efficacy and coping needs further investigation. 
4.8 Conclusions 
Adherence research is hampered by the lack of consensus as to what constitutes 
adherence, let alone the best method of measurement. Co-operation between all 
groups is needed to foster progress in this area, multidisciplinary collaboration and the 
closer involvement of patients is needed to address the problems of non-adherence. 
It is ethically indefensible to deny treatment to groups or individuals on the basis of 
presumptions about their capacity to adhere. Clinical energies would be better spent 
fostering adherence in those who are struggling and supporting those who maintain 
high adherence levels. Clinical psychologists can support this process by offering 
interventions to treat depression, and teaching harm minimisation strategies to those 
engaging in recreational drug use. These are obvious places to start, but further 
investigation of the predictors of non-adherence is needed, and low self-efficacy may 
merit special attention. 
The findings of this study suggest that self-efficacy is related to adherence 
although the direction of causality remains to be established. Clearly, further research 
is needed to clarify the role of self-efficacy. Should it prove to be as significant as the 
results of this study imply, it is quickly and easily assessed and, moreover, amenable 
to intervention. 
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Appendix JI-
Taking Your HIV Medications 
Information Sheet 
We would like to invite you to take part in a research study which we think may be important. 
This information sheet tells you about it. We are interested in looking at the factors which 
make taking antiretroviral drugs difficult. We hope that the information provided will help us 
to devise ways to make taking medication easier for people. 
This research involves completing a written questionnaire which should take about 30 
minutes, maybe more if you are taking many different drugs. If you are happy for us to do 
so, we will contact you in one months time to ask you to fill in part of the questionnaire a 
second time. Whether or not you take part is entirely your choice, and would not affect your 
treatment in any way. 
Please feel free to ask any questions you want to about the research, and we will 
try Our best to answer them. We can be contacted by telephone at the Andrewes Unit 
on 0171 601 7827. 
Please try to answer all the questions that are relevant to the treatments you are 
taking, as the more questions you can answer the more helpful it is. 
We would like to assure you that all information we obtain will remain strictly 
confidential. If you wish to fill in this form only once, this questionnaire is completely 
anonymous. If you are able to help us by filling in the questionnaire in one months time, we 
will ask you to give your clinic number. We would ask you to complete the questionnaire 
when you returned to the clinic for another appointment, or would post the questionnaire to 
you with a stamped addressed envelope. The information will still remain confidential to the 
research team and will be kept separate from your medical notes. If you decide not to be in the 
study, or drop out, this will not put at risk your ordinary medical care. 
General information on patients rights regarding participation in research studies may 
be obtained from your local Community Health Council. 
Please return the completed questionnaire in the sealed envelope provided. 
Thank you very much for taking the time to complete the questionnaire. 
Dr Barbara Hedge Pippa Stallworthy 
Consultant Clinical Psychologist Clinical Psychologist in training 
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WRITTEN CONSENT FORM: 
Perceived Self-Efficacy and Adherence to medication in HIV 
Name of PatientIV olunteer (Block Capitals): 
RECNumber: 
• 
• 
• 
• 
• 
• 
• 
• 
• 
Address: 
The study organisers have invited me to take part in this research. 
I understand what is in the leaflet about the research. I have a 
copy of the leaflet to keep. 
I have had the chance to talk and ask questions about the study. 
I know that the local East London and The City Health Authority 
Research Ethics Committee has seen and agreed to this study. 
I understand that personal information is strictly confidential: I know the 
only people who may see information about my part in the study are the research 
team or an official representative of the organisation which funded the research. 
I freely consent to be a subject in the study. No-one has put pressure on me. 
I know that I can stop taking part in the study at any time. 
I know ifI do not take part I will still be able to have my normal treatment. 
I know that if there are any problems, I can contact: 
Ms Pippa Stallworthy ......................................... . 
Tel. No. 0171 601 7827 ............................. Bleep No.lExt. .................................. . 
Patient' sN olunteer' s: Signature 
Witness's Name 
Witness's Signature: 
Date 
D 
D 
D 
D 
D 
D 
D 
D 
The following should be signed by the Clinician/lnvestigator responsible for obtaining consent 
As the Clinician/lnvestigator responsible for this research or a designated deputy, I confirm that I have 
explained to the patient/volunteer named above the nature and purpose of the research to be undertaken. 
Clinician's Name: 
Clinician's Signature: ..................................... Date: 
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This questionnaire contained identical sets of questions for five drugs. In the interests of brevity, 
only the questions for the first drug have been presented here. Obviously, participants' 
questionnaires included the full set of questions for five drugs. 
Appendix IV-
Taking Your HIV Medications 
We would like some general information about you, this questionnaire is confidential, so we do not need 
your name, but if you are willing to participate in the second part of this study, please write your 
Clinic number .................................... . 
How old are you? ................................ . 
Are you male [ ] or female [ ] (please tick) 
How would you describe your cultural background? (please tick) 
White: Eng/Scot! Welsh [ ] European [ J Greek [ ] 
Greek Cypriot [ ] Irish [ ] Turkish [ ] 
Turkish Cypriot [ ] Orthodox Jewish [ ] Jewish [ ] 
Black Caribbean [ ] Black African [ ] Black (UK) [ ] 
Black Somali [ ] Black Other [ ] Tamil [ ] 
Indian [ ] Sri Lankan [ ] Chinese [ ] 
Pakistani [ ] Bangladeshi [ ] Kurdish [ ] 
Vietnamese [ ] Traveller [ ] Arab [ ] 
Any other ethnic group (please specifY) .............................................. . 
Which country were you born in? ........................................................ . 
Wh . at IS your first language? ................................................................ . 
Do you have a main regular partner? Yes [ ] No [ ] 
If yes, how long have you been in this relationship? .................................... (years/ months) 
Generally speaking, who do you have sex with? (please tick one of the following) 
Men [] Women [ ] Men and Women [ ] 
Who do you live with? (please tick) 
Alone 
With partner 
With friend(s) 
With parents 
[ ] 
[ ] 
[ ] 
[ ] 
With partner and child/children [ ] 
With child/children [ ] 
Other (please specify) 
If you know your latest blood test results: 
What was your last CD4 count (T cell count)? .................... . When was this? ....................... . 
What was your last viral load count? ..................................... When was this? ........................ . 
When did you find out you were HIV positive? ................................... (month and year) 
Have you got an AIDS diagnosis? (please tick) Yes [ ] No [ ] 
When were you given this? ..................................................................... (month and year) 
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How much alcohol do you generally drink each week? ...................................... Units 
(1 Unit = I measure of spirit or I glass of wine or 1/2 pint of lager) 
Please describe .............................................................................................. . 
Please list any non-prescription I recreational drugs you use, and how often you use them 
Drug How often used (per day, week, month) 
Please fill in all all the following questions in relation to the combination therapy I anti-retroviral 
drugs you are taking now. Please tick your response 
How good do you think you are at taking 
drugs as prescribed? 
Excellent [ ] 
Good [ ] 
Reasonable [] 
Poor [ ] 
Disastrous [ ] 
Do you ever stop taking the drugs for any reason, 
ego drug holidays? 
Often [ ] 
Occasionally [] 
Never [ ] 
~Iease say how long you were off drugs the last 
tIme you did this . 
.................................................................. 
...................................................................... 
Do you ever change the times of taking 
your drugs? 
Always [ ] 
Usually [ ] 
Sometimes [ ] 
Occasionally [] 
Never [ ] 
Do you ever change the dose of your drug? 
Always [ ] 
Usually [ ] 
Sometimes [ ] 
Occasionally [] 
Never [ ] 
Which drugs did you stop taking? 
Do you ever take the drugs without adhering to the prescribed regime? (eg. with I without food) 
Always [ ] 
Usually [ ] 
Sometimes [ ] 
Occasionally [] 
Never [ ] 
Appendix IV-
Which of the following drugs are you taking now? 
P.lease tick all the drugs which you are currently taking, noting when you started taking them, and any 
sIde effects you are experiencing. 
Drug tick if taking now Month and year you Side effects I think it's 
AZT 
started taking drug giving me 
(Zidovudine) 
ddi 
(Didanosine) 
ddc 
(Zalcitabine) 
d4T 
(Stavudine) 
3TC 
JLamivudine) 
nelfinavir 
JViracept) 
ritonavir 
I-(Norvir) 
saquinavir 
(Invirase) 
indinavir 
(Crixivan) 
nevirapine 
JViramune) 
delavirdine 
t--
dmp 
I-
1592089 
(Abacavir) 
c!CP prophylaxis 
bactrim / septra 
Jsulfa-trimethoprim) 
dapsone 
I-
aero soli sed 
...pentamidine 
For each of the drugs you have ticked please fill in one of the following sheets. If you are taking only 
one of these drugs you need fill in only one drug sheet. Most people will be taking one, two, three or 
four of these antiretroviral drugs; those that are thought to be the most suitable combination for you. 
You may also be taking medication to prevent PCP, please fill in a sheet for this too. 
Appendix IV-
Most people with HIV have many different pills to take at different times of the day, and many find it 
hard to remember all of them. We need to understand how people with HIV are really doing with their 
pills. Please tell us what you are actually doing. Don't worry about telling us that you don't take all 
your pills. we need to know what is really happening, not what you think we want to hear. 
Please write here the name ofthe first drug you have ticked ................................................... . 
For this drug please answer the following questions 
How many times a day do you take it? times 
---_. 
How many times a day are you supposed to take it? 
How many times did you take the drug yesterday? 
times 
----
times 
----
Did you miss any doses yesterday? Yes [ ] No [ ] 
How many? ____ times 
How many days did you miss a dose of the drug last week? __ times during the past week 
Are there any special instructions which come with this drug? (please specify) 
....................................................................................................................................................................... 
....................................................................................................................................................................... 
................................................................................................. 
Many people find it difficult to follow special instructions about taking their drugs 
How often do you keep exactly to these instructions? 
Always [ ] 
Usually [ ] 
About half the time [ ] 
Occasionally [ ] 
Never [ ] 
~Iease tell me exactly how you take the drug by ticking all the boxes which best describe how you take 
It: 
I always take it I usually take it 
On an empty stomach [ ] On an empty stomach [ ] 
With water [ ] With water [ ] 
Without food [ ] Without food [ ] 
With a snack [ ] With a snack [ ] 
With a full meal [ ] With a full meal [ ] 
At least 2 hours before eating [ ] At least 2 hours before eating [ ] 
At least 2 hours after eating [ ] At least 2 hours after eating [ ] 
W~at happened the last time your routine for taking this drug fell apart? Did you: 
MISS a dose [ ] 
Take a dose late [ ] 
Not folIow special instructions [ ] 
Other .............................................................................................................................................................. . 
........................................................................................................................................................................ 
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(this can be as far back as you remember - it does not have to be in the past week) 
Why did this happen? (please tick) 
Slept/fell asleep [ ] Had too much alcohol, or [ ] 
Change of eating routine [ ] recreational drugs 
Did not want to take medication In hurry, busy schedule, [ ] 
in front of other people [ ] rushing around 
Out of house/away from meds [ ] Don't know [ ] 
Forgot [ ] Drug required refrigeration [ ] 
Sick (NOT side effects)/in hospital [ ] Instructions too difficult [ ] 
Side effectslbad taste [ ] (e.g. take with food, fluid etc.) 
Distracted by something [ ] Ran out of medications [ ] 
Other, (please specify) .............................................................................................................. . 
If you missed a dose, or took it late, how did you realise that you had not taken your drug? 
Someone else reminded you [ ] Just remembered on own at a later time [ ] 
Timer or beeper reminded you [ ] Had leftover pills in planner/bottle [ ] 
Other scheduled events reminded you (e.g. taking another medication, mealtime) [ ] 
How often does something like this happen? 
Every day [ ] 
Nearly every day [ ] 
3 or 4 times a week [ ] 
2-3 times a month 
Once a month 
I or 2 times a week [ ] Less than once a month 
[ ] 
[ ] 
[ ] 
How many times has this happened during the past week? times 
How many times have you taken a dose late during the past week? ____ times 
Taking this drug the way you do, how much benefit do you think you are getting from it? 
All possible benefit [ ] 
Most of the benefit [ ] 
Enough to make it worth taking [ ] 
Some benefit 
Not much benefit 
[ ] 
[ ] 
On a scale of 1-5 where 1 is not sure at all and 5 is very sure, in the next month, how sure are you that 
you will be able to take this medication as directed? 
Not sure 
at all 
2 
Unsure 
3 
Neither sure 
nor unsure 
4 
Sure 
5 
Very 
sure 
How sure are you that you will be able to deal with any problems associated with taking your 
medications? 
Not sure 
at all 
2 
Unsure 
3 
Neither sure 
nor unsure 
4 
Sure 
5 
Very 
sure 
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Please read each item and place a tick in the box opposite the reply that comes closest to how you have 
~een feeling in the past month: Don't take too long over your replies: your immediate reaction to each 
Item will probably be more accurate than a long thought-out response. 
Most of A lot of Occasionally Not at 
the time the time all 
I. I feel tense/ wound up. [ ] [ ] [ ] [ ] 
Definitely Not quite Only a Hardly 
as much as much little at all 
2. I still enjoy things I used to [ ] [ ] [ ] [ ] 
Very definitely Not too Little, doesn't Not at 
and quite badly badly worry me all 
3. I get a sort offrightened feeling as if [ ] [ ] [ ] [ ] 
something awful is about to happen. 
As much as Not quite so Definitely Not at 
I ever could much now not so much all 
4. I can laugh and see the funny side [ ] [ ] [ ] [ ] 
of things: 
A great deal A lot of From time Only 
of the time the time to time occasionally 
5. Worrying thoughts go through my mind: [ ] [ ] [ ] [ ] 
Not at Not Sometimes Most of 
all often the time 
6. I feel cheerful: [ ] [ ] [ ] [ ] 
Definitely Usually Not often Not at all 
7. I can sit at ease and feel relaxed: [ ] [ ] [ ] [ ] 
Nearly all Very Sometimes Not at 
of the time often all 
8. I feel as if I am slowed down: [ ] [ ] [ ] [ ] 
Nearly all Very Sometimes Not at 
of the time often all 
9. ~ get a frightened feeling like butterflies [ ] [ ] [ ] [ ] 
In my stomach: 
Definitely I don't take as I may not I take just as 
much care as take quite as much care 
I should much care as ever 
10. I have lost interest in my appearance: [ ] [ ] [ ] [ ] 
Very much Quite a Not very Not at 
indeed lot much all 
II. I feel restless as if I have to be on [ ] [ ] [ ] [ ] 
the move. 
As much as I Rather less Definitely less Hardly 
ever did than I used to than I used to at all 
12. I look forward with enjoyment to things: [ ] [ ] [ ] [ ] 
13. I get sudden feelings of panic: 
14. I can enjoy a good book, radio or 
TV programme: 
Very often indeed 
[ ] 
Often 
[ ] 
Quite often 
[ ] 
Sometimes 
[ ] 
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Not very often Not at all 
[ ] [ ] 
Not often Very seldom 
[ ] [ ] 
This set of items deals with the ways you've been coping with the stress in your life since you found out 
you were HIV positive. There are many ways to try to deal with problems. These items ask what you've 
~een doing to cope with this one. Obviously, different people deal with things in different ways, but I'm 
Interested in how you've tried to deal with it. Each item says something about a particular way of 
Coping. I want to know to what extent you've been doing what the item says. How much or how 
frequently. Don't answer on the basis of whether it seems to be working or not - just whether or not 
yoU're doing it. Use these response choices. Try to rate each item separately in your mind from these 
others. Make your answers as true FOR YOU as you can. 
On a scale of 1-4 where I is I haven't been doing this at all, 2 is I've been doing this a little bit, 3 is I've 
been doing this a medium amount, and 4 is I've been doing this a lot, please answer the following 
questions. 
I haven't been I've been I've been I've been 
doing this doing this doing this a doing this 
at all a little bit medium amount a lot 
I. I've been turning to work or other I 2 3 4 
activities to take my mind off things. 
2. I've been concentrating my efforts on 2 3 4 
doing something about the situation. 
3. I've been saying to myself, "this isn't 
real". 
2 3 4 
4. I've been using alcohol or drugs to make 2 3 4 
myself feel better. 
5. I've been getting emotional support from 2 3 4 
others. 
6. I've been giving up trying to deal with it. 2 3 4 
7. I've been taking action to try to make the 2 3 4 
situation better. 
8. I've been refusing to believe that it has 2 3 4 
happened. 
9. I've been saying things to let my unpleasant 2 3 4 
feelings escape. 
10. I've been using alcohol or other drugs to 2 3 4 
help me get through it. 
II. I've been trying to see it in a different light, I 2 3 4 
to make it seem more positive. 
12. I've been trying to come up with a strategy 
about what to do. 
13. I've been getting comfort and understanding 1 
from someone. 
14. I've been giving up the attempt to cope. 
IS. I've been looking for something good in 
what is happening. 
16. I've been making jokes about it. 
17. I've been doing something to think about it 
less, such as going to movies, watching TV, 
reading daydreaming, sleeping or shopping. 
18. I've been accepting the reality of the fact 
that it has happened. 
19. I've been expressing my negative feelings. 
20. I've been trying to to find comfort in my 
religion or spiritual beliefs. 
21. I've been learning to live with it. 
22. I've been thinking hard about what steps 
to take. 
23. I've been praying or meditating. 
24. I've been making fun of the situation. 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
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3 4 
3 4 
3 4 
3 4 
3 4 
3 4 
3 4 
3 4 
3 4 
3 4 
3 4 
3 4 
3 4 
On a scale of 1-4 where 1 is not at all true, and 4 is exactly true, please answer the following questions. 
Not at all Barely Moderately Exactly 
true true true true 
I. I can always manage to solve difficult I 2 3 4 
problems if I try hard enough. 
2. If someone opposes me, I can find means 
and ways to get what I want. 
2 3 4 
3. It is easy for me to stick to my aims and 2 3 4 
accomplish my goals. 
4. I am confident that I could deal efficiently 2 3 4 
with unexpected events. 
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5. Thanks to my resourcefulness, I know how 2 3 4 
to handle unforeseen situations. 
6. I can solve most problems if I invest the 2 3 4 
necessary effort. 
7. I can remain calm when facing difficulties 2 3 4 
because I can rely on my coping abilities. 
8. When I am confronted with a problem, I 2 3 4 
can usually think of something to do. 
9. If! am in a bind, I can usually think of 2 3 4 
something to do. 
10. No matter what comes my way, I'm 2 3 4 
usually able to handle it. 
On a scale of 1-5 where 1 is strongly disagree and 5 is strongly agree, please answer the following 
questions. 
I. The doctors and other health professionals 
sometimes ignore what I tell them. 
2. The doctors and other health professionals 
listen carefully to what I have to say. 
3. The doctors and other health professionals 
answer all my questions. 
4. Sometimes the doctors and other health 
professionals use medical terms without 
explaining what they mean. 
5. I trust that the doctors and other health 
professionals have my best interests at heart. 
6. The doctors and other health professionals 
act like I'm wasting their time. 
7. The doctors and other health professionals 
Strongly Disagree Neither Agree Strongly 
disagree agree agree 
nor 
disagree 
2 3 4 5 
2 3 4 5 
2 3 4 5 
2 3 4 5 
2 3 4 5 
2 3 4 5 
2 3 4 5 
treat me in a very friendly and courteous manner. 
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8. The doctors and other health professionals 2 3 4 5 
show little concern for me. 
9. The doctors do not really know what the I 2 3 4 5 
drug is doing to me (I feel like a guinea pig). 
10. IfI take my drugs I am less likely to get ill. 2 3 4 5 
II. My drugs help overcome the tiredness 2 3 4 5 
associated with having AIDS. 
12. I think I will be more closely monitored 2 3 4 5 
at the clinic if I take my drugs. 
13. Following my treatment plan will help me 
to be healthy. 
2 3 4 5 
14. I'll be just as healthy ifI avoid my 
treatment plan. 
2 3 4 5 
1 S. I believe that my treatment plan will help 2 3 4 5 
to prevent my getting IDV related symptoms. 
16. It's hard to believe my treatment plan 2 3 4 5 
will help me. 
17. I think my treatment plan can buy me 2 3 4 5 
time While a cure is developed. 
18. IfI do not take my drugs, I will not be able 2 3 4 5 
to fight AIDS on my own. 
19. Taking my drugs will help reduce worry 2 3 4 5 
that I have about my future health. 
20. I believe that not taking care of infections 
will lead to serious consequences in the future. 
2 3 4 5 
21. I believe that my medications will 2 3 4 5 
manage my IDV. 
22. My treatment plan is too much trouble 
for what I get out of it. 
2 3 4 5 
23. The benefits of my treatment plan outweigh 2 3 4 5 
any difficulty I might have in following it. 
24. The side effects of my drugs outweigh their 2 3 4 5 
benefits. 
25. Following my treament plan is better for 2 3 4 5 
me than not following my treatment plan. 
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26. I believe that my medications will help 2 3 4 5 
prevent complications related to HIV. 
27. If! change my habits to accommodate 2 3 4 5 
my medications it will probably help me. 
28. My medicine makes me feel better. 2 3 4 5 
29. I believe that taking care of infections will 2 3 4 5 
help me feel better. 
30. The thought of having to cope with being 2 3 4 5 
ill puts me off my drugs, 
3 I. Hearing about nasty side-effects 2 3 4 5 
associated with antiretroviral therapy reduces my incentive to take it. 
32. Friends of mine have become ill while taking I 2 3 4 5 
antiretroviral therapy. 
33. Taking my medications interferes with my 2 3 4 5 
normal daily activities. 
34. My HIV is well controlled 2 3 4 5 
35. I eat a good diet and look after myself 2 3 4 5 
so I am unlikely to get ill. 
36. The chances I might develop a new HIV 2 3 4 5 
related infection are pretty high. 
37. My chances of developing AIDS are low. 2 3 4 5 
38. I expect to be free of HIV related infections 2 3 4 5 
in the future. 
39. Others are more likely to develop AIDS 
before I do. 
2 3 4 5 
40. No matter what I do, there's a good chance 2 3 4 5 
of developing a new HIV related infection. 
41. My body will fight off new HIV related 2 3 4 5 
infections in the future. 
42. I am a very resilient person and will fight 2 3 4 5 
against becoming ill. 
43. They will find a cure before I ever develop 2 3 4 5 
AIDS. 
44. I am generally a lucky person and therefore I 2 3 4 5 
feel that good health will be on my side. 
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45. HIV can be a serious disease if you don't 2 3 4 5 
control it. 
46. My HIV will have a bad effect on my 2 3 4 5 
future health. 
47. My HIV will cause me to be sick a lot 2 3 4 5 
48. There are many diseases more severe than 2 3 4 5 
HIV. 
49. HIV is not as bad as people say. 2 3 4 5 
50. HIV is a terrible disease. 2 3 4 5 
51. HIV is just another chronic illness. 2 3 4 5 
52. AIDS is a terminal illness. 2 3 4 5 
53. AIDS can be overcome just like any other 2 3 4 5 
illness. 
54. There is little hope for people with HIV. 2 3 4 5 
55. The risk of death due to AIDS is high. 2 3 4 5 
56. My HIV is no problem to me as long as I 
feel alright. 
2 3 4 5 
57. I believe I will always need my HIV 2 3 4 5 
medications. 
58. Taking care of infections is an important 2 3 4 5 
part of treatment of my HIV. 
59. My doctor tells me I should take antiretro- 2 3 4 5 
viral therapy. 
60. I want to do what my doctor thinks I should 2 3 4 5 
do about antiretroviral therapy. 
61. Members of my immediate family think I 2 3 4 5 
should follow my treatment plan. 
62. I want to do what my immediate family 2 3 4 5 
think I should do about my treatment plan. 
63. My close friends think I should follow my 2 3 4 5 
treatment plan. 
64. My friends have advised me to start taking 2 3 4 5 
antiretroviral therapy. 
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65. I want to do what my close friends think I 2 3 4 5 
should do about my treatment plan. 
66. My partner thinks I should follow my 2 3 4 5 
treatment plan. 
67. I want to do what my partner thinks I 2 3 4 5 
should do about my treatment plan. 
68. My relatives think I should follow my 2 3 4 5 
treatment plan. 
69. I want to do what my relatives think I 2 3 4 5 
should do about my treatment plan. 
70. I have made a commitment to follow my 2 3 4 5 
treatment plan. 
71. My plans do not include following my 2 3 4 5 
treatment regimen. 
72. I intend to follow my my treatment plan 2 3 4 5 
73. I have no intention of following my treatment 1 2 3 4 5 
plan 
74. I intend to take my medications at the correct I 2 3 4 5 
time. 
75. I intend to take my medications in the correct I 2 3 4 5 
doses. 
76. I intend to follow the special instructions for I 2 3 4 5 
my medications. 
77. Lots of things get in the way offollowing 2 3 4 5 
my treatment plan. 
78. I need more assistance to follow my 2 3 4 5 
treatment plan. 
79. I get the help I need to carry out my 2 3 4 5 
treatment plan. 
80. Reading good reports about antiretroviral 2 3 4 5 
therapy would encourage me to take it. 
81. Seeing some of my friends who are not on 2 3 4 5 
antiretroviral therapy become very ill would prompt me to take it 
82. Starting antiretroviral therapy makes me 2 3 4 5 
feel an AIDS diagnosis is pending. 
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83. In am taking antiretroviral therapy now it 2 3 4 5 
wiIJ cease to be effective when my body really needs help. 
84. A large amount of weight loss would make 1 2 3 4 5 
me likely to consider starting antiretroviral therapy. 
85. Whilst my body remains symptom free I 2 3 4 5 
should avoid taking antiretroviral therapy. 
86. It has been difficult to take my medications 2 3 4 5 
as prescribed. 
87. I cannot understand what the doctor told me I 2 3 4 5 
about my medications. 
88. I would have to change too many habits to 2 3 4 5 
take my medications. 
89. I am able to deal with any problems in 2 3 4 5 
following my treatment plan. 
90. Taking care of infections is too difficult 2 3 4 5 
for me. 
91. I believe I can manage my HIV. 2 3 4 5 
92. I can take my medication as prescribed. 2 3 4 5 
93. I am able to take my medicine as often 2 3 4 5 
as the doctor prescribes it. 
94. If I am confused about taking my medic- 2 3 4 5 
ations I am comfortable asking my physician to help me. 
95. I have no control over HIV. 2 3 4 5 
96. I can remember to take my medications. 2 3 4 5 
97. I know how to reach the clinic if! need more I 2 3 4 5 
medications. 
98. If I have side-effects from my medicine, I 2 3 4 5 
am able to have it changed or adjusted. 
99. In take my medicines I feel I am doing 2 3 4 5 
something to fight HIV. 
100. If I run out of my medicines I wait until my I 2 3 4 5 
next appointment to get refills 
10 I. I am comfortable carrying my medicines with 2 3 4 5 
me if! go out. 
Appendix IV-
102. My HIV would be worse if I did nothing 2 3 4 5 
about it. 
103. I am able to take my medications at the correct I 2 3 4 5 
time. 
104. I am able to take my medications in the correct I 2 3 4 5 
doses. 
105. I am able to follow the special instructions for 2 3 4 5 
my medications 
106. I am able to change my habits to accommodate 2 3 4 5 
my medications. 
Is there anything else about your medications which you think is important which you would like to tell 
us? 
Thank you for taking the time to complete this questionnaire 
